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DIRECT DIGITAL ENGAGEMENT OF PATIENTS AND 
DEMOCRATIZING HEALTH CARE 
Dov Greenbaum JD, PhD, CIPP/E†
Smartphones and social media have changed the way we 
integrate technology into our daily lives, and this is quickly bleeding 
into diverse medical fields. Many social media sites provide specialty 
forums for the sick to interact with their peers. Unfortunately, these 
sites are mostly unregulated environments where advertisers can prey 
on the desperate but unwary, people can provide their unwarranted 
but seemingly authoritative medical opinions, and clinicians can troll 
for cohorts for their studies. These sites also encourage users to share 
personal and private medical information; oftentimes that medical 
information implicates not only the immediate patient, but also her 
extended family members who might be similarly experiencing, but 
more privately, the same or similar medical conditions. 
Just like social media brings medical consultancy to the masses, 
smartphones have brought medical diagnostics to just about anyone 
who can download a mobile device software application (app). 
Diagnostic and other medical apps often take advantage of the ever-
shrinking size of wearable technologies, as well as advances in 
computing that can offer doctors, patients, and third parties powerful 
medical tools on their portable computing devices. 
The FDA has provided little to no guidance in the Wild West of 
patient related social media sites. Although it has issued voluntary 
guidelines for apps intended to diagnose, treat, or prevent diseases 
many questions remain unanswered. Without clear rules for these 
relatively new classes of medical devices, and with the threat of 
regulatory and monetary repercussions for app developers, the FDA 
may be chilling development of new and useful medically related 
applications. 
Both patient-oriented social media sites and many mobile 
medical applications (MMAs) are particularly useful and relevant for 
†Assistant Professor, Molecular Biophysics and Biochemistry, Yale University Director,
The Zvi Meitar Institute for Legal Implications of Emerging Technologies, Radzyner Law 
School, Interdisciplinary Center, Herzliya. 
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the growing class of chronically ill patients. While the potential for 
heavy-handed regulation of MMAs may chill development in this area 
and hurt this aforementioned population, the lack of any oversight in 
patient oriented social media sites may also potentially harm this 
demographic by not enforcing any filter to a largely lay and 
desperate population. 
This paper will provide brief reviews of the state of the art for 
these medically related technologies and review the regulatory and 
legal aspects of these similar but distinct technologies. The paper will 
suggest both a hybrid regulatory and technological solution for 
MMAs and a mostly-regulatory solution for policing patient oriented 
social media sites. These proposed rules will also take into account 
related issues such as evolving social norms, including the rapid rise 
of the quantified-self-trend and changes in perceptions of privacy. 
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INTRODUCTION
Historically, the Internet and related technologies helped to 
democratize many aspects of society.  This was, and continues to be 
the case with healthcare. Traditionally, medicine was a paternalistic 
profession that actively promoted God-complexes amongst its 
practitioners.1 These and other high barriers to entry limited the 
practice of medicine and the development of medical devices to the 
professionals and to corporations with, or with access to, deep 
pockets. 
Now, anyone who can program a smartphone or tablet 
application (app) can potentially produce a medical device. Similarly, 
social media sites aimed particularly at patient populations have 
empowered patients to help each other and provide additional 
important care and support, and perhaps surprisingly, useful clinical 
data. Both concurrent advances in the democratization of health care 
have the potential to provide substantial benefit. Both, however, also 
raise a number of serious concerns. 
The first part of this paper will suggest a less nuanced and more 
novel approach to mobile health (mHealth) taxonomy than 
predecessor papers. This relatively simple approach will be dictated 
principally by the goal of promoting innovation without jeopardizing 
safety. This paper argues that under the current and proposed regimes, 
innovation is not promoted2 and safety is actually jeopardized. 
The second part of the paper will provide arguments as to why 
even those applications that taxonomically typically fall in what 
should be an unregulated group of apps really require a hybrid 
regulatory and technological solution to promote innovation while 
simultaneously helping and protecting an ever growing demographic. 
In the third section, this paper will segue to social media sites 
aimed at patient subgroups, describing and defining them in detail. 
The fourth section will raise real and relevant concerns with regard to 
patient oriented social media sites and suggest a mostly regulatory fix. 
The final section will provide conclusions. 
Notably, this paper hopes to be ahead of the curve regarding the 
issues raised. As such, data relating to some of the concerns described 
 1. Maureen Dowd, Decoding the God Complex, N. Y. TIMES (Sept. 28, 2011), available
at http://www.nytimes.com/2011/09/28/opinion/dowd-decoding-the-god-complex.html.
 2. Marsha Blackburn, et al., Letter From Congressional Representatives to the Food & 
Drug Admin. and the Fed. Trade Comm’n, U.S. CONGRESSMAN MARSHA BLACKBURN (Apr. 3, 
2012), http://blackburn.house.gov/uploadedfiles/letter_from_congress_to_fda_and_fcc__
3apr2012.pdf.
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herein may be sparse at best. 
I. MOBILE MEDICAL APPLICATIONS
Under Section 201 of the Federal Food, Drug, and Cosmetic Act, 
a device is “an instrument, apparatus, implement, machine, 
contrivance, implant, in vitro reagent, or other similar or related 
article, including any component, part, or accessory, which is... 
intended for use in the diagnosis of disease or other conditions, or in 
the cure, mitigation, treatment, or prevention of disease, in man or 
other animals.”3 The U.S. Food and Drug Administration (FDA) has, 
on a number of occasions, decided that the “intended use clause” 
includes software; for example, mobile medical applications (MMAs) 
fall under FDA purview as medical devices.4,5
The relatively recent term “mHealth” relates to both mobile 
health portable electronics software applications and related and/or 
unrelated appliances.6 This paper focuses on the former—mobile 
medical applications (MMAs) in FDA parlance. Their closely related 
counterparts, mobile health applications (MHAs),7 will be subsumed 
under the MMA heading. Currently, most MMAs are classified as 
Class II devices under current FDA guidelines, i.e., “higher risk 
devices than Class I that require greater regulatory controls to provide 
reasonable assurance of the device’s safety and effectiveness.”8
 3. 21 U.S.C. § 321(h) (2012). 
 4. U.S. Food & Drug Admin., Mobile Med. Applications: Guidance For Indus. & FDA 
Staff, U.S. FOOD AND DRUG ADMIN., (Feb. 9, 2015), http://www.fda.gov/downloads/
MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM263366.pdf. 
 5. Suzan Onel, Where the “App” World and FDA Collide: Current Status of the FDA’s 
Regulation of Medical Device Software and Mobile Medical Apps, in INSIDE THE MINDS,
RECENT DEVS. IN FOOD & DRUG LAW 153, 155 (2014), http://www.klgates.com/files/
Publication/7642d9b2-62b4-45ff-bf9e-7aa2ad4a7496/Presentation/PublicationAttachment/
af8747a0-a280-4d16-8f8c-7b4a48de30a0/Inside_the_Minds_Onel_Chapter.pdf
 6. See Anne Marie Helm & Daniel Georgatos, Privacy and mHealth: How Mobile 
Health “Apps” Fit Into a Privacy Framework Not Limited to HIPAA, 64 SYRACUSE L. REV.
131, 134 (2014), for a definition of mHealth (“[W]hen a provider of healthcare services uses 
connected and interactive mobile computing4 to produce, access, transmit, or store data for the 
provision of healthcare services to patients, or when a patient or consumer uses connected and 
interactive mobile computing to produce, access, transmit, store, or otherwise share data for a 
health-related purpose.”). 
 7. Ceara Treacy et al., Mobile Health & Med. Apps: Possible Impediments to 
Healthcare Adoption, in PROC. OF THE SEVENTH INT’L CONF. ON EHEALTH, TELEMEDICINE, &
SOCIAL MEDICINE 199, 199 (Marike Hettinga et al. eds., 2015).
 8. U.S. Food & Drug Admin., What Does it Mean for FDA to “Classify” a Medical 
Device?, ABOUT FDA (Dec. 28, 2015), available at http://www.fda.gov/AboutFDA/
Transparency/Basics/ucm194438.htm.
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There has been a rapid growth of health-related applications for 
online platforms.9 According to at least one study, by 2015 there were 
over 165,000 mobile health apps available for users to download.10
According to another study, the market for mHealth apps will reach 
$26 billion globally by 2017.11 Further, another recent survey 
suggests that at least 10% of the US population have already 
downloaded an mHealth application and another 46% would be 
interested in using the technology to monitor and manage health vitals 
and other health-related data.12
Actual efforts to track the types of mHealth apps available on the 
myriad of mobile platforms available to users today, estimated at over 
40,000,13 including smartphones, tablets, phablets and the like, seem 
reminiscent (in retrospect) of the sad efforts to catalogue the internet 
in the early days of the World Wide Web. With development of 
mHealth apps rapidly increasing, and with new apps appearing almost 
daily and older apps falling out of use, these efforts seem, by their 
very nature, Sisyphean. 
These impressive numbers notwithstanding, the medical 
community still knows very little about the uptake and overall 
actionable usage of mHealth despite the large number of studies in the 
field.14
In general, these health-related applications for mobile 
technology fall under the rubric of Health IT. Under current law, three 
“agencies,” including: the Food and Drug Administration (FDA), the 
Office of the National Coordinator for Health Information 
Technology (ONC) and the Federal Communications Commission 
 9. Eric Topol, The Future of Medicine Is in Your Smartphone, WALL ST. J. (Jan. 9, 
2015), available at http://www.wsj.com/articles/the-future-of-medicine-is-in-your-smartphone-
1420828632.
 10. IMS Institute, Patient Adoption of mHealth Use, IMS HEALTH (Sept. 2015), available 
at http://www.imshealth.com/en/thought-leadership/ims-institute/reports/patient-adoption-of-
mhealth#ims-form. 
 11. Ralf-Gordon Jahns, The Market for mHealth App Services Will Reach $26 Billion by 
2017, RESEARCH2GUIDANCE (2015), available at http://www.research2guidance.com/the-
market-for-mhealth-app-services-will-reach-26-billion-by-2017.
 12. Deloitte, mHealth: A Check-Up on Consumer Use, DELOITTE, http://
www2.deloitte.com/content/dam/Deloitte/us/Documents/life-sciences-health-care/us-chs-
mhealth-infographic.pdf. 
 13. Scott Rupp, mHealth Stats: Mobile Apps, Devices and Solutions, ELEC. HEALTH
REPORTER (Dec. 10, 2015), available at http://electronichealthreporter.com/mhealth-stats-
mobile-apps-devices-and-solutions/.
 14. Mark Tomlinson et al., Scaling Up mHealth: Where is the Evidence?, 10 PLOS MED.
1 (2013). 
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(FCC), were recently tasked with determining a “proposed strategy 
and recommendations on an appropriate, risk-based regulatory 
framework pertaining to health information technology, including 
mobile medical applications, that promotes innovation, protects 
patient safety, and avoids regulatory duplication.”15 In addition, the 
Federal Trade Commission (FTC) has been cracking down on 
mHealth apps.16 For example, the FTC recently fined companies with 
apps that misrepresent their medical abilities, e.g., the ability to detect 
cancers.17
This work will focus particularly on the FDA, which has a clear 
regulatory authority over software related to medical devices.18
According to the most recent list of FDA guidance priorities, the 
agency may choose to reevaluate its role in medical software, perhaps 
in light of congressional efforts to cabin it.19
However, thus far, the FDA has unreservedly failed in its review 
of MMAs. On average, the FDA takes 67 days to review a MMA; by 
this point, the app has often been updated and likely changed such 
that the initial product no longer resembles the app submitted for 
review.20 Moreover, only a minute percentage of the available apps 
have even been reviewed by the FDA; the majority of them have been 
classified as Class II medical devices.21
Whereas most analyses of the current state of affairs for health-
related apps tend to fault the FDA’s guidance documents for any 
15. FDA SAFETY & INNOVATION ACT (FDASIA), Pub. L. No. 112-144, § 618, 126 Stat. 
993 (2012). 
 16. See, e.g., FTC Watch, More Consumer Protection Action on the Way at the FTC,
FTC WATCH ISSUE NO. 823 (Feb. 14, 2013) available at http://ftcwatch.com/series/823. 
 17. Federal Trade Commission, FTC Cracks Down on Marketers of “Melanoma 
Detection” Apps, PRESS RELEASES (Feb. 23, 2015), available at https://www.ftc.gov/news-
events/press-releases/2015/02/ftc-cracks-down-marketers-melanoma-detection-apps.
18. Richard A. Merrill, The Architecture of Government Regulation of Medical 
Products, 82 VA L. REV. 1753 (1996).
 19. See, e.g., Darius Tahir, FDA Puts Interoperability Guidance on Back Burner,
MODERN HEALTHCARE (Jan. 9, 2015), available at http://www.modernhealthcare.com/article/
20150109/NEWS/301099953.
 20. Greg Slabodkin, FDA’s Bakul Patel: For Mobile Medical Apps, Patient Safety First,
FIERCE MOBILE HEALTHCARE (May 23, 2013), available at http://
www.fiercemobilehealthcare.com/story/fdas-bakul-patel-mobile-medical-apps-patient-safety-
first/2013-05-23.
 21. John Avellanet, Majority of Mobile Health Apps Class II Devices for FDA,
COMPLIANCE ZEN (July 2013), available at http://www.compliancezen.com/compliance_zen/
2013/07/majority-mobile-health-apps-class-ii-devices-fda.html; see also Ting-Yu Wang et al., 
mAuditor: Mobile Auditing Framework for mHealth Applications, in PROC. OF THE 2015
WORKSHOP ON PERVASIVE WIRELESS HEALTHCARE 7, 7 (Emmanuel Baccelli et al. eds, 2015). 
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number of limitations, omissions and other errors, this paper will 
argue that much of the proposed FDA regulation of mHealth should 
be done away with entirely, with any regulation limited to only a 
small subset of apps. Under this initial proposal most consumer apps, 
arguably the bulk of the current catalogue of MMAs, would remain 
essentially unregulated under the FDA. 
To some degree, this is the goal of the Preventing Regulatory 
Overreach To Enhance Care Technology (PROTECT) Act of 201422
which ultimately was not passed.23 As per US Senator Deb Fischer’s 
(R-Neb) office: 
Under current law, the FDA can use its definition of a medical 
device to assert broad regulatory authority over a wide array of low-
risk health IT, including mobile wellness apps, scheduling software, 
and electronic health records. The PROTECT Act gives clarity to 
FDA’s regulatory process to focus on products that pose a legitimate 
risk to human health. This more effective, risk-based framework 
boosts patient safety by prioritizing FDA’s attention to technologies 
that pose the greatest health risk. It also protects low-risk health IT 
from unnecessary regulatory burdens that stifle opportunities for job 
creation, innovation, and improved care.24
Somewhat counterintuitively to the MMA arguments, this paper 
will also argue that social media sites focused on patient groups ought 
to be more regulated, albeit perhaps not by the FDA. This might even 
go against conventional wisdom at the FDA, which after years of 
delays,25 effectively dropped social media from its 2011 guidance 
agenda,26 but later re-included it.27
 22. THE PROTECT ACT, S. 2007, 113th Cong. (as introduced, Feb. 10, 2014), available
at https://www.govtrack.us/congress/bills/113/s2007/text/. 
 23. Id.
 24. Angus King, King, Fischer Introduce Legis. to Protect Jobs, Prevent Overregulation 
in Growing Health IT Industry, ANGUS KING UNITED STATES SENATOR FOR MAINE, (Feb. 10, 
2014), available at http://www.king.senate.gov/newsroom/press-releases/king-fischer-introduce-
legislation-to-protect-jobs-prevent-overregulation-in-growing-health-it-industry/. 
 25. Breaking – Its Official – FDA Delaying Social Media Guidance Until at Least Q1 
2011, EYE ON FDA (Dec. 2010), available at http://www.eyeonfda.com/eye_on_fda/2010/12/
breaking-its-official-fda-delaying-social-media-guidance-until-at-least-q1-2011.html.
 26. FDA Drops Social Media from Its 2011 Guidance Agenda, PHARMA MARKETING
BLOG (June 1, 2011), http://pharmamkting.blogspot.com/2011/06/fda-drops-social-media-from-
its-2011.html.
 27. U.S. Food & Drug Admin., Guidance Agenda:  New & Revised Draft Guidances 
CDER is Planning to Publish During Calendar Year 2016, U.S. FOOD AND DRUG ADMIN. (Jan.
22, 2016), http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/UCM417290.pdf 
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A.  MMA Taxonomy 
Taxonomies have been developed in an attempt to catalogue the 
wide array of potentially regulatable mobile medical applications,28
including a taxonomy by the FDA itself that confusingly makes an 
important practical distinction between those apps that pose “a risk to 
patients” and those apps that “pose a low risk to patients,” a 
distinction poorly clarified in the FDA’s appendix to their guidance 
documents.29
The Food and Drug Administration Safety and Innovation Act 
(FDASIA) “expands the FDA’s authorities and strengthens the 
agency’s ability to safeguard and advance public health.”30  Included 
in this authority, a workgroup was “ charged with providing expert 
input on issues and concepts identified by the Food and Drug 
Administration (FDA), Office of the National Coordinator for Health 
IT (ONC), and the Federal Communications Commission (FCC) to 
inform the development of a report on an appropriate, risk-based 
regulatory framework pertaining to health information technology 
including mobile medical applications that promotes innovation, 
protects patient safety, and avoids regulatory duplication.”31 But even 
the FDASIA working group’s more fleshed-out stratification of risk 
does not take into account many of the concerns raised herein with 
regard to concerns with MMAs.32
While some of these taxonomies attempt to place each individual 
type of application into its most relevant and distinctive classification, 
this paper proposes perhaps a crude and consequentially more useful 
taxonomy. 
A binary taxonomy is particular useful, if not actually necessary, 
and is even more simplistic than the current FDA April 2014 
 28. See, e.g., Miloslava Plachkinova et al., A Taxonomy of mHealth Apps—Security and 
Privacy Concerns, in PROC. OF THE 2015 48TH HAW. INT’L CONF. ON SYS. SCIENCES (HICSS)
3187, 3187 (Tung X. Bui et al. eds., 2015). 
 29. U.S. Food & Drug Admin., supra note 4, at 23. 
 30. U.S. Food & Drug Admin., Food and Drug Administration Safety and Innovation 
Act, REGULATORY INFORMATION (Oct. 6, 2015), available at http://www.fda.gov/
RegulatoryInformation/Legislation/SignificantAmendmentstotheFDCAct/FDASIA/
ucm20027187.htm.
 31. HealthIT.gov, FDASIA, HEALTHIT.GOV (June 17, 2015), available at https://
www.healthit.gov/facas/health-it-policy-committee/hitpc-workgroups/fdasia.
32. Sarah P. Slight & David W. Bates, A Risk-Based Regulatory Framework for Health 
IT: Recommendations of the FDASIA Working Group, 21 J. AM. MED. INFORMATICS ASS’N, No. 
e2, 2014, at e181-4.
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recommendations.33 Many software developers in the mHealth field 
may simply be startups34 that are not as savvy to FDA regulation and 
oversight as their more experienced medical device manufacturer 
counterparts; as such they may be discouraged from innovating in this 
area if they lack the ability to relatively easily assess their regulatory 
environment from the outset.35 This is particularly problematic given 
that in many cases the FDA has reverted to applying its standard 
medical device methodologies in assessing MMAs.36
The goal of this effort would be to simplistically divide apps into 
manageable categories that reflect the subsequent nature of their 
regulation. The more basic the divisions, the easier they are to apply, 
particularly for the uninitiated.  And the less likely that the uninitiated 
startup innovators in this field will be confused, the less likely  
innovation will be chilled.  For example, given that Class II devices 
face increased regulations and costs of doing business,37 MMA 
developers will want to know beforehand, or before huge expenses 
have been sunk, whether they fall into a class associated with high 
costs or a class associated with low regulatory costs. 
mHealth is particularly being pursued aggressively by startups 
that are relatively FDA-naïve. For example, venture capital investors 
have pumped more than a quarter billion dollar in the start of 2013 
into mHealth.38 Even with the need for regulatory oversight, the FDA 
should be careful to promote rather than inhibit innovation in this area 
 33. U.S. Food & Drug Admin., FDASIA Health IT Report, ABOUT FDA (April 21, 2014), 
available at http://www.fda.gov/AboutFDA/CentersOffices/
OfficeofMedicalProductsandTobacco/CDRH/CDRHReports/ucm390588.htm.
 34. See, e.g., MHEALTH STARTUPS, https://angel.co/mhealth (last visited Jan. 10, 2016); 
MHEALTH, https://www.crunchbase.com/category/mhealth/
a3b491d88d66b566a059c14322895d77 (last visited Jan. 10, 2016); MOBIHEALTHNEWS, http://
www.mhealthnews.com/blog/42-startups-cusp-mhealth-innovation (last visited Jan. 10, 2016); 
ROCK HEALTH  https://rockhealth.com/reports/digital-health-2015-midyear/ (last visited Jan. 10, 
2016);
STARTUP HEALTH INSIGHTS https://www.startuphealth.com/content/insights-2015q2 (last 
visited Jan. 10, 2016). 
 35. Robert L. Garrie & Pamela E. Paustian, mHealth Regulation, Legislation, and 
Cybersecurity, in MHEALTH 45, 45 (Springer US, 2014). 
36. Vanessa Coleman, FDA Approved?: Examining the FDA’s Approach to Mobile 
Medical Apps and its Sufficiency, LAW SCHOOL STUDENT SCHOLARSHIP SETON HALL LAW
(2015), http://scholarship.shu.edu/cgi/viewcontent.cgi?article=1681&context=student_
scholarship.
 37. Avellanet, supra note 21. 
 38. Nanette Byrnes, Mobile Health’s Growing Pains, MIT TECH. REVIEW (July 21, 
2014), available at http://www.technologyreview.com/news/529031/mobile-healths-growing-
pains/.
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as it has already been shown that mHealth apps are beneficial in the 
health care environment, allowing for more rapid and accurate health 
care decisions by health care providers.39
To this end, this paper argues for a dualistic regulatory oversight 
test. An application necessitates some form of regulatory oversight by 
the FDA when: (1) a mHealth app is configured and/or otherwise 
designed to be used in a clinical environment [e.g., in conjunction 
with electronic health records (EHRs) such as in a doctor’s office, 
ambulance, clinic, or hospital] and (2) that application uses one or 
more sensors (onboard and/or external) to perform a calculation based 
on data obtained in real or near-real-time from the patient, her 
hospital bed or other patient related data. This is slightly broader than 
the FDA’s own regulatory system which, while seeming very broad in 
applying its oversight to mainly those apps “whose functionality 
could pose a risk to patient safety if the [MMAs] were not to function 
as intended,”40 is in practice very narrow. The extent of that 
regulatory control should be related to the destined usage of the 
application and the nature of the application. The regulation of these 
apps should include a standardization of data collection and storage, 
as well as standardized application program interfaces (APIs), so that 
different apps can easily and coherently communicate with each 
other. 
All other mHealth apps, such as consumer directed apps, do not 
need any regulatory oversight whatsoever by the FDA. However, they 
must be clearly marked as being recreational/non-clinical to ward off 
this proposed governmental oversight. In this sense, the application 
must also not make any clinical claims related to its utility, or market 
itself as such. This clear demarcation might include a clickwrap 
agreement, and/or a perpetual clickwrap feature in which the user 
must click through a simple statement noting the limited (i.e. 
recreational) use of the application every time the user employs the 
application. This suggestion follows conventional wisdom wherein 
nearly a third of correspondents to a 2013 Deloitte survey believed 
that mobile applications are likely to have potential errors.41 And in 
 39. Mirela Prgomet et al., The Impact of Mobile Handheld Technology on Hospital 
Physicians’ Work Practices and Patient Care: A Systematic Review, 16 JOURNAL OF THE 
AM. MED. INFORMATICS ASS’N 792, 792 (2009); Lex van Velsen et al., Why Mobile Health 
App Overload Drives Us Crazy, and How to Restore the Sanity, MED. INFORMATICS & 
DECISION MAKING, NO. 23, 2013, at 1 (2013). 
 40. U.S. Food & Drug Admin., supra note 4, at 4. 
 41. Deloitte, supra note 12. 
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any event, it would be unfeasible for any government organization to 
effectively police and regulate the growing ranks of mHealth apps, 
particularly in light of the above concerns. Moreover, in addition to 
the errors, there are other legitimate health-related concerns for 
consumer-facing applications, such as over-reliance on non-human 
analysis and the inability of many of the applications to find 
secondary medical problems that might otherwise be discovered in a 
face-to-face doctor visit.42
The types of apps that would fall under the regulation-free 
designation would include many of those that are, or could be, 
regulated by the FDA as proposed under their guidance documents. 
B.  Why MMAs Should Not Be Marketed As Medical Devices 
Not only must mHealth applications for use in clinical settings 
be regulated, they actually ought to be regulated and consistently 
monitored. The nature of the technology demands such oversight.  For 
instance, consider the following scenario. There are hundreds of 
millions of smartphones in the world with a myriad number of distinct 
and diverse models running a wide variety of operating systems and 
their respective versions. Data from 2013 suggests that only about 4% 
of all Android mobile phones and devices were running the most up-
to-date version of the operating software; the rest were running any 
number of other variations, which does not include the multitude of 
free and/or otherwise applications on these devices that alter basic 
operating aspects of the phone either unintentionally or even 
maliciously.43
Each smartphone contains a number of sensors, i.e., a sensor 
being something that measures a physical quantity and converts that 
physical quantity into a digital or analog signal that can be read by the 
onboard processing hardware, including those that measure motion, 
orientation, and environmental conditions. These sensors can be 
hardware, software, or a hybrid of the two. 
“Hardware-based sensors are physical components built into a 
handset or tablet device. They derive their data by directly measuring 
specific environmental properties, such as acceleration, geomagnetic 
field, strength, or angular change. Software-based sensors are not 
 42. Stephen McInerney, Can You Diagnose Me Now? A Proposal to Modify the FDA’s 
Regulation of Smartphone Mobile Health Applications with a Pre-Market Notification and 
Application Database Program, 48 U. MICH. J.L. REFORM 1073, 1079 (2015).
 43. MARC GOODMAN, FUTURE CRIMES: EVERYTHING IS CONNECTED, EVERYONE IS
VULNERABLE AND WHAT WE CAN DO ABOUT IT 107 (2015). 
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physical devices, although they mimic hardware-based sensors. 
Software-based sensors derive their data from one or more of the 
hardware-based sensors and are sometimes called virtual sensors or 
synthetic sensors. The linear acceleration sensor and the gravity 
sensor are examples of software-based sensors.”44
Motion sensors can include gravity sensors, accelerometers, 
linear acceleration sensors, rotational vector sensors tracking chips 
(which can distinguish between a phone holder’s walking and 
driving) and gyroscopes. Orientation sensors can include geomagnetic 
field sensors, positional sensors, global positioning sensors and the 
like. Environmental sensors can include infrared, force, ambient air 
temperature sensors and local air pressure sensors. Additionally, 
environmental sensors can include proximity, illumination, and 
humidity sensors. Also included in the group of environmental 
sensors are photometers, barometers, and thermometers.45
Other onboard sensors include microphones and pedometers. 
The increasingly powerful cameras on smartphones are also useful 
sensors. Many recent models of smartphones also include fingerprint 
sensors. Some phones even include sensors that can detect harmful 
radiation. All in all, these sensors can have various distinct operating 
parameters including different ranges, power requirements, and varied 
resolution abilities. 
Each smartphone model could potentially have a distinct set of 
sensors and each of these sensors may interact differently (albeit 
sometimes minimally so) with the wide variety of operating systems 
and their respective versions: “Note: Android does not require device 
manufacturers to build any particular types of sensors into their 
Android-powered devices, so devices can have a wide range of sensor 
configurations.”46
Downloaded software, not to mention malicious code, could 
affect the way sensors read physical quantities. In some examples, 
this affect could be imperceptible yet nevertheless actionable. 
Additionally, even smartphone protective cases may affect the 
onboard sensors, if only minimally, not to mention the various bumps 
and bangs typical of the daily wear and tear on a smartphone. For 
example, it has been shown that something as seemingly benign as 
 44. SENSORS OVERVIEW, http://developer.android.com/guide/topics/sensors/sensors_
overview.html (last visited Oct. 24, 2015). 
 45. Id.
 46. Id.
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prolonged exposure to refrigerator magnets can decalibrate some 
smartphone magnetometers. 
Given all this variability it would seem nearly impossible to 
design a reliable, accurate, and medically appropriate consumer 
oriented mHealth app that could take into account, in its assessment 
of the patient’s health, all of the potential variability associated with 
the sensors and the resulting data they collect. Uncalibrated, 
smartphone sensors are often error prone and unreliable for a number 
of tasks.47, 48 Even with minute changes, we run the risk of potentially 
drastically different and potentially misguided results that could 
wrongly direct an individual concerned as to their health. 
To deal with all of this uncertainty some have suggested the 
mHealth applications rely only on a subset of sensor data from 
smartphones such as subset of sensors that are onboard trusted 
sensors, e.g., “sensors whose readings cannot be easily manipulated 
by the smartphone’s OS or by applications.”49 However, these trusted 
sensors may represent only a small subset of onboard, useful, and/or 
relevant sensors. 
Under any regulatory regime, the reliability of the application 
might need to be reassessed after each and every operating system 
upgrade or patch, or application software upgrade, and for each new 
model and their respective subtypes. For these reasons alone, it would 
seem to be prudent for the FDA to keep a close regulatory eye on 
mHealth apps to confirm that each one is constantly updated to 
account for changing technology. But, for these same reasons, it 
would be nearly impossible for the FDA to keep tabs on all of the 
direct to consumer products and all their iterations that might be 
developed to deal with all of the software and hardware changes and 
versions. 
“The FDA is woefully understaffed and under-resourced to 
oversee these things, particularly given the number of the thousands 
of apps that are [most likely] under FDA’s jurisdiction.”50 This is 
47. Antonio Villasante & Cristina Fernandez, Measurement Errors in the Use of 
Smartphones as Low-Cost Forestry Hypsometers, 48 SILVA FENNICA, NO. 5:1114, 2014, at 
1.
48. JEFFREY R. BLUM ET AL., Smartphone Sensor Reliability for Augmented Reality 
Applications, Mobile and Ubiquitous Systems, in MOBILE & UBIQUITOUS SYSTEMS:
COMPUTING, NETWORKING, AND SERVICES, 127-38 (2013).
 49. Alec Wolman et al., Using Trusted Sensors to Monitor Patients’ Habits, MICROSOFT
RESEARCH (2010), http://research.microsoft.com/en-us/um/people/alecw/healthsec-2010.pdf.
 50. Bahar Gholipour, Should You Trust Health Apps on Your Phone? LIVE SCIENCE (July 
25, 2014), available at http://www.livescience.com/47021-health-apps-fda-regulation.html 
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compounded by the sheer number of users who are likely to use this 
software, with some estimates suggesting that there could be more 
than one and half billion users worldwide by 2018.51 With such 
staggering numbers, and the ability to easily provide hundreds of 
thousands of copies of software to patients, even minor missteps can 
have huge repercussions. In light of the common conception that the 
FDA is unequipped and understaffed for these sorts of regulatory 
oversight projects, some in Congress have suggested that mHealth 
ought to be excluded from the FDA’s purview.52,53
C.  Regulatory Oversight Should Be Constrained In Most 
Situations
The quantified-self movement uses a lot of non-standardized 
consumer technologies to quantify aspects of our lives, including 
products like Fitbit, and Apple Health. In addition to the lack of 
standardization, many of these products vary in their ability to 
accurately measure different health-related data.54, 55  These
technologies and their associated apps are, in many respects, similar 
to MMAs, although arguably distinct in the nature of the analysis of 
the data collected by these technologies, and/or the stated uses of that 
data or analyzed data56
However, without the ability to provide an absolutely clear 
demarcation where quantified self apps end and mHealth apps begin a 
standardized definition of what is and what isn’t a consumer mHealth 
application is likely to remain elusive. Nevertheless, both types of 
software apps aimed at the consumer market should be able to escape 
(quoting a health law expert, Nathan Cortez, associate professor of law at Southern Methodist 
University Dedman School of Law in Dallas, Texas). 
 51. Mary Beth Hamel et al., FDA Regulation of Mobile Health Technologies, 371 NEW
ENG. J. MED. 372, 372-79 (2014). 
 52. The Sensible Oversight for Technology Which Advances Regulatory Efficiency Act 
of 2013 (SOFTWARE Act), H.R. 3303, 113th Cong. (1st Sess. 2013). 
 53. The Preventing Regulatory Overreach to Enhance Care Technology Act of 2014 
(PROTECT Act), S.2007, 113th Cong. (2nd Sess. 2014). 
 54. Judit Takacs et al., Validation of the Fitbit One Activity Monitor Device During 
Treadmill Walking, 17 JOURNAL OF SCI. & MED. IN SPORT 496-500 (2014). 
 55. J. Adam Noah et al., Comparison of Steps and Energy Expenditure Assessment in 
Adults of Fitbit Tracker and Ultra to the Actical and Indirect Calorimetry, 37 JOURNAL OF MED.
ENG’G & TECH. 456-62 (2013). 
 56. U.S. Food & Drug Admin., General Wellness: Policy for Low Risk Devices Draft 
Guidance for Industry and Food and Drug Administration Staff, U.S. FOOD AND DRUG ADMIN.
(Jan. 20, 2015), http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/
guidancedocuments/ucm429674.pdf.
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the need for any regulation whatsoever by making it clear that they 
cannot be trusted for clinical use, for example, as described above. 
This relatively simple method to clearly determine from the 
outset whether or not your mHealth app will be subject to FDA 
regulation  (either you are Clinical or Recreational) should provide 
software with the freedom to innovate unimpededly without the 
overhanging fear of FDA regulations making their product 
unprofitable or unmarketable. 
It is important to note that under this binary taxonomy, the 
important clinical innovations would not be lost. Eventually, the 
relatively mature innovation that has already passed through the 
general consumer recreational marketplace could be transferred to the 
clinical setting once the technology is proven in the recreational 
setting, and once the programmers and their backers better understand 
their product. And, hopefully at this juncture, the software producers 
will be better able to bring their more mature application through the 
FDA regulatory process. 
Much of this may become quickly moot anyway. Once the 
novelty of having your smartphone conduct medical tests wears off, 
mHealth developers will likely quickly appreciate the liability 
concerns associated with the unknowable hardware and software with 
which is their application will interact, as described above. As such, 
future computational based developments will likely migrate to the 
cloud where variability associated with processing can be better 
limited and controlled. Further, whereas personal data collected on a 
smartphone, unless encrypted, represents a significant possibility of a 
breach of privacy,57 the cloud could potentially provide a safe and 
secure environment for collected mHealth patient data. 
Further, more astute mHealth app developers will likely pull 
away completely from smartphone-based analysis (since it is too risky 
given its unpredictable nature and inability to control all the moving 
parts) and market more profitable, controllable and reliable stand-
alone devices. These stand-alone devices will likely be designed to 
not suffer from many of the general concerns related to using 
smartphones, including, network delays, limited bandwidth, 
confounding and conflicting software applications, viruses, malware, 
battery life, storage capacity and the like. For example, by 2014 there 
were nearly four million distinct malware software applications 
 57. Robert L. Garrie & Pamela E. Paustian, mHealth Regulation, Legislation, and 
Cybersecurity, in MHEALTH 45 (2014). 
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focused on mobile devices.58 The growth of these devices will likely 
coincide with the growth of related telemedicine technologies. 
Under the proposed binary taxonmy, in the end, it is likely that 
the only mHealth apps that will be regulated by the FDA will be those 
that in clinical settings perform “patient-specific analysis and 
providing patient specific diagnosis or treatment recommendations. 
Examples of mobile apps that perform sophisticated analysis or 
interpret data  (electronically collected or manually entered) from 
another medical device include: apps that use patient-specific 
parameters and calculate dosage or create a dosage plan for radiation 
therapy; Computer Aided Detection software (CAD); image 
processing software; and radiation therapy treatment planning 
software.”59 These apps will run on stand-alone devices, designed 
specifically for the health market and in particular to avoid the 
uncertainties and liabilities associated with software apps running on 
old, hacked or otherwise non-optimal operating systems and 
technology platforms. 
D.  MMAs And Chronic Disease Patients 
However, the underlying theories of this taxonomy fail when it 
comes to mHealth-related applications for the chronic disease 
demographic.60 This is a relatively large percentage of the sick 
population: “In 2012, among civilian, noninstitutionalized US adults, 
approximately half (49.8%, 117 million) had at least 1 of 10 selected 
chronic conditions. More specifically, 24.3% had 1 chronic condition, 
13.8% had 2 conditions, and 11.7% had 3 or more conditions.”61
Chronic diseases are the leading cause of morbidity and mortality in 
the United States.62
Part of treating chronic diseases is the promotion of healthy 
 58. Lianne Caetano, Mobile Malware in 2014, MCAFFEE BLOG CENTRAL (Mar 25, 
2014), http://blogs.mcafee.com/consumer/mobile-malware-2014. 
 59. U.S. Food & Drug Admin., supra note 4. 
 60. See, e.g., Christina Farr, Former Google Executive’s App Aims to Tackle Chronic 
Illness, REUTERS (Oct. 28, 2014), available at http://www.reuters.com/article/2014/10/28/us-
healthcare-tech-vida-idUSKBN0IH1SV20141028. 
 61. Brian W. Ward et al., Multiple Chronic Conditions Among US Adults: A 2012 
Update, CENTERS FOR DISEASE CONTROL AND PREVENTION  (April 17, 2014), http://
www.cdc.gov/pcd/issues/2014/pdf/13_0389.pdf.
 62. Ctrs. for Disease Control and Prevention, Chronic Disease Overview, CHRONIC
DISEASE PREVENTION AND HEALTH PROMOTION (Feb. 23, 2016), available at http://
www.cdc.gov/chronicdisease/overview/.
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lifestyles and the self-management of the disease.63 Self-management 
of chronic disease has been shown in studies to generally improve the 
health of patients and reduce the need for hospitalization, which itself 
exposes the patient to opportunistic infections.64 Furthermore, some 
have estimated that mHealth technologies could offer 197 billion 
dollars in savings over the next two decades in treating chronic 
diseases.65
As such, this demographic may make up a large percentage of 
the mHealth market —in the United States, 86% of health care 
spending relates to the treatment of chronic disease66 and this cannot 
be easily glossed over. It might include cancer, diabetes, heart 
disease, chronic obstructive pulmonary disease, HIV, and even 
obesity. These patients are the ones most likely to benefit  from the 
constant monitoring and the constant connectivity of consumer 
electronics, allowing patients to self-manage their disease or provide 
for the ability to have timely interventions by a health professional 
when necessary,67 provided that they actually use the applications. 
And, in clinical studies where chronic disease patients used mHealth 
technology, benefits were seen.68
With this demographic in mind, perhaps the above proposed 
taxonomy should include a hybrid group of applications that are both 
clinical and consumer directed, e.g., the passive collection of clinical 
or near-clinical grade data from consumer devices that can provide 
 63. Caroline Free, et al., The Effectiveness of Mobile-Health Technology-Based Health 
Behaviour Change or Disease Management Interventions for Health Care Consumers: A 
Systematic Review, 10 PLOS MEDICINE 1 (2013). 
 64. Kate R. Lorig, et al., Evidence Suggesting That a Chronic Disease Self-Management 
Program Can Improve Health Status While Reducing Hospitalization: A Randomized Trial, 37 
MEDICAL CARE 5, 5-14 (1999). 
 65. Robert Litan, Vital Signs via Broadband: Remote Monitoring Technologies Transmit 
Savings, Enhances Lives, AT&T (Oct. 24, 2008), https://www.corp.att.com/healthcare/docs/
litan.pdf.
 66. Ctrs. for Disease Control and Prevention, Chronic Disease Prevention and Health 
Promotion, CTRS. FOR DISEASE CONTROL AND PREVENTION (Jan. 23, 2016) available at http://
www.cdc.gov/chronicdisease/.
 67. Tara McCurdie et al., mHealth Consumer Apps: The Case for User-Centered Design,
46 BIOMEDICAL INSTRUMENTATION & TECH. 49 (2012). 
 68. Charlene C. Quinn et al., Welldoc™ Mobile Diabetes Management Randomized 
Controlled Trial: Change in Clinical and Behavioral Outcomes and Patient and Physician 
Satisfaction, 10 DIABETES TECH. & THERAPEUTICS 160, 160-68 (2008); Charlene C. Quinn et 
al., Cluster-Randomized Trial of a Mobile Phone Personalized Behavioral Intervention for 
Blood Glucose Control, 34 DIABETES CARE 1934 (2011); but c.f. Bree Holtz & Carolyn 
Lauckner, Diabetes Management Via Mobile Phones: A Systematic Review, 18 TELEMEDICINE
& E-HEALTH 175, 175-84 (2012) (noting that many of the studies lacked the requisite statistical 
rigor to come to medically relevant conclusions). 
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health care professionals with timely access to relevant data. 
This hybrid group would include apps directed at consumers 
with chronic disease that require some form of constant monitoring. 
Alternatively, this group could also include apps directed to clinical 
study participants who need to track some or more of their vitals data 
off-site. This hybrid group might also interface with EHRs, albeit at 
home not at a health-care related institution. 
But this hybrid group would also highlight many of the practical 
concerns raised above that cannot be simply solved by regulation or 
legislation. The need for some oversight is pressing and the drawn out 
iterative process of developing internal oversight controls, conformity 
assessment tools, certification and assessment schemes and general 
best practices (as suggested by the April 2014 FDASIA Health IT 
Report)69 will fail to meet the urgent and exigent needs of the industry 
today.  The same is true for IEEE and/or ISO standard proposals.70
Rather, a more technical solution may be necessary to overcome 
the issues raised and given the competing interests of public policy: 
dependable software with limited regulatory oversight. 
E.  Technological Soultions To Policy Concerns With Chronic 
Disease Oriented MMAS 
To this end, a potential solution for both chronic disease apps as 
well as potentially even all MMAs currently regulated or otherwise 
would include a software or hardware interface to technologically 
deal with many of the concerns raised. This shared boundary between 
apps and anything else those apps communicate with would allow for 
the regulated and controlled exchange of information between any 
two different components of an mHealth environment. This could 
include an interface between the MMA and the underlying operating 
system and hardware or the MMA and an online component. 
Developed under the auspices of a Federal agency, the 
middleware could be designed explicitly to deal with the many 
technical and regulatory concerns raised above.  Like the 
Telecommunications Act of 1996, signed into law by President Bill 
 69. U.S. Food & Drug Admin., FDASIA Health IT Report: Proposed Strategy and 
Recommendations for a Risk-Based Framework, U.S. FOOD AND DRUG ADMIN. (Apr. 2014), 
http://www.healthit.gov/sites/default/files/fdasiahealthitreport_final.pdf.
 70. E.g., ISO/IEEE 11073-10418:2014 Health Informatics—Personal Health Device 
Communication—Part 10418: Device Specialization—International Normalized Ratio (INR) 
Monitor, INT’L ORG. FOR STANDARDIZATION (Mar. 1, 2014), available at http://www.iso.org/
iso/iso_catalogue/catalogue_tc/catalogue_detail.htm?csnumber=61897.
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Clinton, that mandated that a specific technology (colloquially known 
as  a V-chip) be introduced into every new television,71 smartphones 
could also be required to include this middleware in all new phones 
and/or software updates. 
The middleware could employ one or more open APIs 
(Application Programming Interface) such that any app developer 
could easily write their code to gather and/or distribute sensor data 
through the software interface.72 This middleware could also create 
and enforce a single unified standard of sensor data such that 
independent of the hardware or the software (e.g., the smartphone and 
its operating system). Further, the middleware would also enforce a 
standardization of values resulting from sensors that allow for 
consistent readings independent of device hardware and software — 
for example, all values could be required to be presented using the 
metric system. Importantly, this standardization would allow for 
portability across hardware and software platforms and between other 
mHealth apps, something that seems to be widely lacking for most 
mHealth apps.73
This middleware could also enforce a standardization of medical 
information formats, limiting the usability of data that is not provided 
to the middleware from an mHealth app in standard format. This 
forced standardization would further promote good, reasonable and 
accurate use of collected health-related data. This standardization via 
the middleware could piggyback on current efforts to enforce 
standards in health care. For example, EHR standards could be 
imported and required for use in mHealth apps.74,75
In summary, the middleware proposed herein would be a 
standardized, calibrated, uniform platform to allow a standardized 
 71. Telecommunications Act of 1996, Title V – Obscenity And Violence, Pub. L. No. 
104-104, 110 Stat. 56 (1996). 
 72. See, e.g., OPEN API INITIATIVE, openapis.org (last visited Aug. 10, 2015)  
(Describing how APIs form the connection between apps and third parties, and elaborating on 
how vendor neutral and open APIs can increase connectivity between apps and third party apps 
and/or data sources.) 
73. Shoko Miyagawa et al., Data Portability in Mhealth—Can We Retain Our Life Log 
When Changing Apps, Devices, or Mobile Platforms?, 143rd APHA Annual Meeting and 
Exposition, APHA (Oct. 31-Nov. 4, 2015).
74. Marco Eichelberg et al., Electronic Health Record Standards – A Brief Overview,
PROCEEDINGS OF THE 4TH IEEE INTERNATIONAL CONFERENCE ON INFORMATION AND 
COMMUNICATIONS TECHNOLOGY (2006).
75. A. Begoyan, An Overview of Interoperability Standards for Electronic Health 
Records, PENNSYLVANIA STATE UNIVERSITY (2007), http://citeseerx.ist.psu.edu/viewdoc/
download?doi=10.1.1.131.4421&rep=rep1&type=pdf.
112 SANTA CLARA HIGH TECH. L.J. [Vol. 32 
communication between onboard and linked sensors and the 
individual mHealth applications. It is important that this middleware 
appear frictionless to the user and the developers, otherwise they will 
become a burden that users will attempt to work-around. 
The middleware need not be specific to consumer based mHealth 
apps, and in fact, may be very useful in clinical apps as well. The 
middleware could be backwards compatible to legacy devices and 
constant updates would allow it to avoid becoming obsolete.76
To this end, the software might employ an onsite- or cloud based 
up-to-date database of hardware and software such that the necessary 
error corrections and fudge factors could be applied to varied sensor 
readings such that after these algorithms would be applied, the 
distinctions between all the varied types of hardware the software 
would be irrelevant. All applications receiving data from this software 
would start at the same baseline. 
This same software could also employ regular calibrations and 
system checks both periodically during runtime and perhaps always at 
boot-up to confirm that the hardware has not been damaged through 
regular wear and tear and that the system’s software has not been 
compromised as a result of uploaded code, malicious or otherwise. 
The software interface could also be written such that it would 
not allow mHealth apps to circumvent it and acquire data from the 
sensors directly and not through the regulatory approved interface. 
Users might be given the opportunity to opt out of this limitation 
provided that they provide informed consent through, for example, a 
clickwrap license.77
As an additional benefit, this same middleware could also 
regulate the outflow of information from the individual mHealth apps, 
requiring that, for example, all mHealth collected data be encrypted 
for privacy protection. This encrypted outflow would employ one or 
more known encryption methodologies, i.e., limited and controlled 
encryption. This limited and controlled encryption would help 
promote interoperability among different devices and systems and 
 76. Philip A. Berstein, Middleware: a model for distributed system services, 39.2
COMMUNICATIONS OF THE ACM 86 (1996),  http://delivery.acm.org/10.1145/240000/230809/
p86-bernstein.pdf?ip=129.210.115.240&id=230809&acc=ACTIVE%20SERVICE&key=
80B0E63637265656%2EC2822F75119601FF%2E4D4702B0C3E38B35%2E4D4702B0C3E38
B35&CFID=668242243&CFTOKEN=78929755&__acm__=1473981831_
09dba1f1823bd284ac448a70487df11b (describing some of the benefits of middleware, 
particularly when there are many different platforms that need to interact). 
 77. Nathan J. Davis, Presumed Assent: The Judicial Acceptance of Clickwrap, 22 
BERKELEY TECH. L.J. 577 (2007). 
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network infrastructures, and in cases of emergency or legal need, it 
would be clear to the necessary agencies how to decrypt the data. 
Moreover, rather than relying on varying levels of encryption for each 
different application, this middleware could provide up-to-date, top-
of-the-line encryption. 
Further, software that used the mHealth app that did not encrypt 
data, or prevented the middleware from encrypting the data, would 
not work unless the user clicked through a sensibly composed 
clickwrap license78 that made it clear that the data could only be 
employed for recreational use. Similarly, a clickwrap license would 
be required to be signed off on prior to sharing collected data. 
Having a software solution as a required interface would limit 
the necessary regulatory outlays of the regulating agency. Much of 
the necessary complexity described above would, rather than being 
spread across literally thousands of applications, would all reside in 
one software program. Whether the application is developed by the 
FDA, some other regulatory agency or commercial group is not 
relevant. It is sufficient only that it would require some regulatory 
oversight to confirm that it remains accurate and useful. 
Pushing this idea further, one could imagine a protected 
marketplace, run perhaps by the FDA and/or relevant NGO or 
governmental organizations where applications designed for clinical 
home use by chronic disease patients could be distributed, akin to the 
Apple iTunes market place, and distinct from the more open Android 
marketplaces. Like other proprietary app marketplaces, apps within 
the marketplace would have to pass a minimal standard. Further 
doctors could be encouraged to professionally review mHealth apps 
in this chronic disease marketplace by giving them continuing 
medical education (CME) credit for time spent in evaluating software. 
Evaluations would not be anonymous to prevent laziness and slacking 
and doctors and medical professionals would be encouraged to 
provide useful feedback that could be viewed by patients within the 
marketplace. 
Apple’s “Health”79 (formerly Healthkit) may be the closest 
approximation of this goal for their proprietary devices: “Heart rate, 
calories burned, blood sugar, cholesterol — your health and fitness 
apps are great at collecting all that data. The new Health app puts that 
 78. Id.
 79. HEALTH: AN INNOVATIVE NEW WAY TO USE YOUR HEALTH AND FITNESS
INFORMATION, http://www.apple.com/ios/whats-new/health/ (last visited Oct. 31, 2015). 
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data in one place, accessible with a tap, giving you a clear and current 
overview of your health. With HealthKit, developers can make their 
apps even more useful by allowing them to access your health data, 
too.”80
F.  Other mHealth Concerns 
In addition to the regulation of health care applications, and all 
concomitant bureaucracy associated with regulation, there remain a 
number of generalized concerns associated with mHealth. These 
concerns are not limited to the clinical apps, but are also relevant, if 
not even more so, for the unregulated recreational non-clinical 
applications.
Thus, even though we have argued that mHealth applications 
need not necessitate FDA oversight, particularly when they are 
specifically aimed at consumers and marked as recreational, 
nevertheless the continued growth of the non-medical consumer 
mHealth market raises a number of real and relevant concerns that 
need to be addressed. 
For instance, “[c]linicians and patients are adopting mobile 
technologies faster than providers can protect security and privacy. 
It’s time to play catch-up.”81 Additionally, “[d]ata security and patient 
privacy are top issues facing everyone in the mHealth landscape, with 
regulators assessing the need for more rules and oversight, lawmakers 
calling on vendors to tighten data sharing practices and physicians 
citing the two issues as reasons for not embracing mHealth 
technology. A recent study cites the healthcare sector as the most 
immature industry in terms of personal mobile device security, 
endpoint compliance discovery and remediation.”82
These security concerns are nearly insurmountable within the 
current status quo of cell phone usage. “Mobile phones are one of the 
most insecure devices that were ever available, so they’re very easy to 
trace; they’re very easy to tap.”83 Thus, it should come at no surprise 
 80. Id.
 81. Bari Faudree & Mark Ford, Security and Privacy in Mobile Health, WALL ST. J.
(Aug. 6, 2013), available at http://deloitte.wsj.com/cio/2013/08/06/security-and-privacy-in-
mobile-health/.
 82. Judy Mottl, mHealth Success Hinges on Security, Workflow Adaptability, FIERCE
MOBILE HEALTHCARE (October 4, 2014), available at http://www.fiercemobilehealthcare.com/
story/mhealth-success-hinges-security-workflow-adaptability/2014-10-04.
 83. Evgeny Morozov, Evgeny Morozov Quotes, BRAINY QUOTE (Sept. 10, 2015), 
available at http://www.brainyquote.com/citation/quotes/quotes/e/evgenymoro555021.html?ct=
Evgeny+Morozov; GOODMAN, supra note 43. But cf. Tim Cook, A Message to Our Customers,
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that smartphones are huge security risks for health-related data. 
In general, privacy concerns typically go hand-in-hand with 
security concerns, e.g., that someone will gain access to their personal 
and/or medical data and use it for fraud and/or identity theft. The 
promise to protect (and thus regulate) “security” of medical devices, 
(and now apps under the MMA guidance) is even spelled specifically 
in the FDA mission statement.84 Nevertheless, even in areas where 
FDA regulation has been longstanding, there remain huge gaps in the 
regulation of security protocols for software.85
Security breaches, which have doubled in past year with an 
estimated 60% of android phones infected by malicious code,86 can 
lead to a loss of consumer trust. 87 Even when security holes are 
identified it can be difficult if not impossible to have all consumers 
patch their software. 
This inability to currently properly accommodate all of the 
private data purportedly being generated by mHealth apps is a huge 
liability for health care professionals and serves as a disincentive to 
popularize potentially useful apps. 
According to the National Committee on Vital and Health 
Statistics (NCVHS), “the statutory public advisory body to the 
Secretary of Health and Human Services on health information 
policy”,88 “Health information privacy is an individual’s right to 
control the acquisition, uses, or disclosures of his or her identifiable 
health data. Confidentiality, which is closely related, refers to the 
obligations of those who receive information to respect the privacy 
interests of those to whom the data relate. Security is altogether 
different. It refers to physical, technological, or administrative 
safeguards or tools used to protect identifiable health data from 
unwarranted access or disclosure.”89
APPLE (Feb. 16, 2016), available at http://www.apple.com/customer-letter/ (Apple’s opposition 
to the FBI’s request to make a new version of the iPhone operating system). 
 84. U.S. Food & Drug Admin., What We Do, U.S. FOOD & DRUG ADMIN. (Dec. 7, 2015), 
available at http://www.fda.gov/aboutfda/whatwedo/. 
 85. See Eric D. Perakslis, Cybersecurity in Health Care, 371 NEW ENG. J. MED. 395 (Jul. 
31, 2014). 
 86. Smart Clinic, Breaking Down the mHealth Security Landscape, SMART CLINIC BLOG
(Sept. 25, 2014), http://smartclinicapp.com/breaking-mhealth-security-landscape/. 
 87. See Faudree & Ford, supra note 81. 
 88. NATIONAL COMMITTEE ON VITAL AND HEALTH STATISTICS, http://ncvhs.us/ (last 
visited Oct. 31, 2015). 
 89. Simon P. Cohn, Recommendations Regarding Privacy and Confidentiality in the 
Nationwide Health Information Network, NATIONAL COMMITTEE ON VITAL AND HEALTH
STATISTICS (June 22, 2006), available at http://www.ncvhs.hhs.gov/recommendations-reports-
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It is thought that there is a growing threat of cyberattacks 
associated with medical devices putting personal and private health 
information at risk for being disclosed: in this area, the FDA, which 
generally includes adverse event reporting and post-approval reports 
in its regulation of medical devices, lacks forward-looking approach 
to protect and prevent mHealth data before the malicious events 
occur. (Cybersecurity is conspicuously lacking from the MMA 
guidance documents).90
The substantial amount of literature relating to the general issues 
of patient privacy is one of the most pressing concerns of mHealth. 
Private data in the mHealth context can be thought of as broader than 
in the standard healthcare context. This is simply due to the reality 
that a broader array of data can be, and is, collected by mHealth 
applications. This data includes daily fitness data, exercise related 
information, calorie intake data, even levels of social interaction, and 
the more standard health-related information including glucose levels, 
blood oxygenation levels, heart rate, breathing rates, among others. 
Moreover, storing this data digitally makes it more portable and as 
such more likely to move via malicious actors. 
With data saved locally on the device there are a number of 
opportunities for the personal health-related data to be captured and 
collected. Most simplistically, phones can be misplaced or hacked, as 
can large data online repositories. In fact, all the major online 
repositories, i.e., cloud computing providers, have been hacked.91
This data is not only at risk for privacy breaches while it is being 
collected by your smartphone  using remote sensors, but it is also at 
risk while it sits on the phone and while it is transit between other 
systems, for example, where data is transferred wirelessly from 
smartphones to third party devices or cloud resource. 
Transit of health-related and other privacy data can be a 
necessity, particularly for apps that require remote monitoring by 
health-related professionals.  Additionally, data tends to be in transit 
during coordinated sharing between health care professionals that 
share the patient, and with remote/cloud storage such as, for example 
in commercial/consumer Personal Health Record (PHR) systems like 
presentations/june-22-2006-letter-to-the-secretary-recommendations-regarding-privacy-and-
confidentiality-in-the-nationwide-health-information-network/. 
 90. See Katherine B. Wellington, Cyberattacks on Medical Devices and Hospital 
Networks: Legal Gaps and Regulatory Solutions, 30 SANTA CLARA COMPUTER & HIGH TECH.
L.J. 139 (2014). 
 91. GOODMAN, supra note 43, at 117. 
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the now discontinued Google Health,92 Microsoft’s HealthVault,93 or 
the Dossia consortium,94 or in an institutional Electronic Health 
Record (EHR) System. 
Data transfers between phones and other devices, including the 
cloud, can be tapped and health data can be extracted and collected 
for any number or reasons, including, for example, identity theft, 
unauthorized access to data, or unauthorized and damaging disclosure 
of otherwise private health data.95,96Transit of data also occurs via 
wireless technologies such as Bluetooth and/or WiFi from wireless 
sensor devices or networks, e.g., wireless medical sensor networks 
(WMSNs). Data is often stolen or sniffed in transit. In some instances, 
femtocells and other devices that act as wireless network extenders, 
have been set up for malicious and illegal purposes. These extenders 
can trick phones into thinking that they are legitimate waypoints 
within the cellular network, wherein in reality they are designed to 
illicitly capture data.97
In addition to the most obvious victim of leaked information, the 
consumer, leaked data is also embarrassing for the corporate and 
health-related bodies involved in the processing and transferring of 
private patient data. Moreover, the leaking, stealing or sniffing of data 
could also expose risk-averse application developers to fines and 
lawsuits, thereby chilling innovation. 
Guidelines could attempt to enforce encryption protocols to 
protect data. However, in consumer-facing apps, this type of 
enforcement is not feasible. Solutions exist, but they require the 
unprecedented and unlikely cooperation of the multitudes of mHealth 
app developers and/or the consumers to be implemented.98 It is 
 92. GOOGLE HEALTH, http://www.google.com/intl/en_us/health/about/ (last visited Oct. 
31, 2015). 
 93. HEALTH VAULT, https://www.healthvault.com/il/en (last visited Oct. 31, 2015). 
 94. DOSSIA CONSORTIUM, http://dossia.org/ (last visited Oct. 31, 2015). 
 95. David Kotz, A Threat Taxonomy for mHealth Privacy (2011), http://
ieeexplore.ieee.org/stamp/stamp.jsp?arnumber=5716518.
 96. Consumer Reports, Your Secrets Aren’t Safe: Data Thieves are After Your Most 
Private Info—When You Use Wi-Fi and Shop Online, and Even When You Store Files in the 
Cloud, CONSUMER REPORTS (May 2014), available at http://www.consumerreports.org/cro/
magazine/2014/07/your-secrets-aren-t-safe/index.htm.
 97. Lauren Walker, Fake Cell Towers Allow the NSA and Police to Keep Track of You,
NEWSWEEK (Sept. 5, 2014), available at http://www.newsweek.com/what-cell-ls-those-
ominous-phony-towers-268589; Kim Zetter, Hacker Spoofs Cell Phone Tower to Intercept 
Calls, WIRED (July 31, 2010), available at http://www.wired.com/2010/07/intercepting-cell-
phone-calls.
 98. Bruno M. Silva et al., A Data Encryption Solution for Mobile Health Apps in 
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unlikely that even suggested guidelines will be headed; app 
developers uninterested in the cumbersome and user-unfriendly 
encryption are unlikely to impose encryption without consumer 
demand. Additionally, consumers are unlikely to demand encryption 
since both hardware level encryption and software level encryption 
can affect phone performance and impact battery life; Google recently 
disclosed that up to 95% of its unencrypted traffic comes from mobile 
devices.99 Most consumers do not protect their mobile phones with 
any technological protections.100, 101,102 Even consumers that encrypt 
data on their own devices are unlikely to be sufficiently 
technologically savvy to encrypt communications between their 
applications and third parties. Moreover, the government itself is 
against strong encryption for smartphone data.103, 104
Privacy concerns might also result in a chilling effect, not only in 
the development of the mHealth apps and technologies, but in the 
prescription of their use by doctors wary of the fines and headaches 
associated with even minor HIPAA infractions.105,106 Under the 
HIPAA Privacy Rule, HIPAA oversight is limited to privacy breaches 
associated with Protected Health Information (PHI), which only 
relates to identifiable information on an individual’s mental and/or 
physical health, and only when that information is held or transmitted 
Cooperation Environments, 15 J. MED. INTERNET RES. (2013). 
 99. GOOGLE TRANSPARENCY REPORT, https://www.google.com/transparencyreport/https 
(last visited March 15, 2016). 
 100. Sophos, 67 Percent of Consumers Don’t Have Password Protection on Their Mobile 
Phones, SOPHOS PRESS RELEASES (Aug. 9, 2011), available at https://www.sophos.com/en-us/
press-office/press-releases/2011/08/67-percent-of-consumers-do-not-have-password-protection-
on-their-mobile-phones.aspx.
 101. Herb Weisbaum, Most Americans Don’t Secure Their Smartphones, CNBC (Apr. 26, 
2014), available at http://www.cnbc.com/2014/04/26/most-americans-dont-secure-their-
smartphones.html.
 102. Donna Tapellini, Smart Phone Thefts Rose to 3.1 Million in 2013: Industry Solution 
Falls Short, While Legislative Efforts to Curb Theft Continue, CONSUMER REPORTS (May 28, 
2014), available at http://www.consumerreports.org/cro/news/2014/04/smart-phone-thefts-rose-
to-3-1-million-last-year/index.htm.
 103. FBI Director Lashes Out at Apple, Google for Encrypting Smartphones, RUSSIA
TODAY (Sept. 26, 2014), available at http://rt.com/usa/190980-comey-fbi-encryption-phones/. 
 104. Maggie Ybarra, FBI Pushes to Weaken Cell Phone Security, Skirt Encryption, THE
WASH. TIMES (May 26, 2015), available at http://www.washingtontimes.com/news/2015/may/
26/fbi-push-to-weaken-cell-phone-security-skirt-encry.
 105. See Health Information Technology for Economic and Clinical Health (HITECH) 
Act, 42 U.S.C. § 1320d-5(a)(3) (2013) (describing the four-tier penalty system for HIPAA 
violations).
 106. Pardeep Kumar & Hoon-Jae Lee, Security Issues in Healthcare Applications Using 
Wireless Medical Sensor Networks: A Survey, 12 SENSORS 55, 65-73 (2012). 
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by a covered entity. Security breaches of ePHI fall under the HIPAA 
security rule which sets out technical administrative and physical 
standards to protect electronic persona health information.107 Under 
the HITECH Act,108 breach notifications need to be provided in 
instances of security failures and fines were raised significantly. 
Again this is limited only to covered entities; as such HIPAA 
regulations do not cover consumer directed mHealth applications. 
And while HIPAA is regulated by The U.S. Department of 
Health and Human Services (HHS), not the FDA,109 perhaps future 
efforts can include cooperation between the FDA and HHS in battling 
cyber security threats in the mHealth environment, including putting 
together best practices. Until such time, consumers need to rely on 
state and in some instances, federal consumer protection laws such as 
those enforced by the FTC.110
In addition to privacy concerns, a particularly important issue 
associated with the consumer mHealth apps is the concern that users, 
lacking the proper context and technical and medical knowledge will 
misunderstand or misinterpret the results, data, or information 
provided by the mHealth applications. 
In some examples, this might result in rash prophylactic 
decisions carried out without medical supervision.  These worried 
well individuals,111 (iPodchondriacs112) some even clinically 
hypochondriacs, might limit otherwise normal behaviors, or otherwise 
act in unnecessary ways thinking that they are sick. Not only are these 
people harming themselves, but they might also become a drain on 
the medical system and insurers, visiting doctors and/or emergency 
rooms for unnecessary checkups or procedures. Unfortunately, the 
worried well are a lucrative demographic for mHealth developers, not 
only will they likely purchase health-related smart phone applications, 
 107. Modifications to the HIPAA Privacy Rule, 67 Fed. Reg. 53,182 (Aug. 14, 2002) 
(codified as 45 C.F.R. §§ 160, 164). The HIPAA Privacy Rule took effect on April 14, 2004. Id.
at 53, 183. 
 108. The Health Information Technology for Economic and Clinical Health Act 
(HITECH) was enacted under Title XIII of the American Recovery and Reinvestment Act of 
2009, Pub. L. No. 111–5, 123 Stat. 115 (2009). 
 109. 45 C.F.R. § 160.103. 
 110. Helm & Georgatos, supra note 6, at 151-67. 
 111. Maxine Frith, Are You One of the Rising Numbers of the ‘Worried Well’?, THE
TELEGRAPH (July 20, 2014), available at http://www.telegraph.co.uk/health/dietandfitness/
10977877/Are-you-one-of-the-rising-numbers-of-the-worried-well.html.
 112. M-Health: Health and Appiness, THE ECONOMIST (Feb. 1, 2014), available at http://
www.economist.com/news/business/21595461-those-pouring-money-health-related-mobile-
gadgets-and-apps-believe-they-can-work.
120 SANTA CLARA HIGH TECH. L.J. [Vol. 32 
but it is expected that they will also purchase related peripherals that 
interact or integrate with smartphones and their applications at 
additional costs. Some analysts actually specifically track this 
demographics’ uptake of mHealth-related technology. According to 
Machina research, for example, the worried well currently account for 
“61.8m connected devices in 2014 globally, increasing to more than 
477m in 2023.”113
On the other side of the spectrum are the walking sick. This 
demographic include groups of individuals that might otherwise need 
medical care, but have been lulled into a false sense of medical 
security based on results from their inaccurate or improperly used 
mHealth apps. They too can be a drain on insurers and health care 
providers, ignoring symptoms based on a false sense of security until 
the problems become bigger, more costly and impossible to ignore. 
II. DEVELOPING WORLD ACCESS TO HEALTH CARE
The pros and cons mentioned above relate primarily to the 
United States and other developed nations.  However, in some areas 
of the world, particularly where access to healthcare is severely 
limited, and outbreaks of major diseases are somewhat common,114
mHealth can be a societal boon, particularly with the burden of 
chronic diseases rising in middle and low income countries.115 As 
such, there have been numerous calls to scale up mHealth 
technologies in these areas.116
While access to health care is limited, particularly in rural areas 
of the world and in Africa, access to mobile technology, which is 
more affordable than most other basic services in Africa, is on a 
continual climb. Africa’s mobile subscriber growth is effectively the 
fastest in the world, with estimates of over a billion mobile phone 
subscribers by 2015 and mobile penetration of almost 95% of the 
 113. Andy Castonguay, Consumerization of Connected Health Devices Sparks Innovation 
and Growing Investment, M2M NOW (May 20, 2014), available at http://www.m2mnow.biz/
2014/05/20/20697-consumerization-connected-health-devices-sparks-innovation-growing-
investment/. 
 114. Lizabeth Paulat, Mobile Health Apps to Become First Line of Defense in Outbreaks,
VOICE OF AMERICA (Nov. 4, 2014), available at http://www.voanews.com/content/mobile-
health-apps-to-become-first-line-of-defense-in-africa-outbreaks/2507423.html. 
 115. Robert Beaglehole et al., Alma-Ata: Rebirth and Revision 3-Improving the Prevention 
and Management of Chronic Disease in Low-Income and Middle-Income Countries: A Priority 
for Primary Health Care, 372 LANCET 940, 940 (2008). 
 116. See Tomlinson, supra note 14. 
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population.117
Mobile technology may bring about significant improvements to 
a healthcare system that is “constrained by high population growth, 
high disease burden, inadequate workforce, widespread rural 
populations and limited financial resources? The answer is mobile.”118
Mobile communications may bring a wealth of knowledge to 
Africa that possesses the potential to “reimagine healthcare across 
Africa.”119 “From combating malaria to detecting counterfeit drugs, 
the emergence of mobile health solutions is saving more lives than 
international aids.”120  In a 2013 report by PricewaterhouseCoopers, 
the initiatives in Africa could potentially save a million lives by 
2017.121
The mobile penetration notwithstanding, in spite of extensive 
efforts,122 Africa still has the lowest rate of mHealth app adoption in 
the world, and in general lower and middle income countries lag 
behind their more developed neighbors.123 Perhaps the promotion of 
standardized app middleware, as described above would further the 
uptake of, in some instances, vital software and technologies. 
However, like the concerns mentioned above, even developing 
nations need to be cognizant of the particular pitfalls of mHealth 
technology – particularly its limitations and unintended consequences 
of too much or unclear information and data. 
These same set of concerns, including privacy, security, walking 
sick and worried well, exist not only in the area of mHealth, but also 
in more recent developments in social media, which similarly 
 117. Amr Shady, Africa’s Mobile Market: Untapped Potential for Global Investment, CP-
AFRICA (Dec. 8, 2014), available at http://www.cp-africa.com/2014/12/08/africas-mobile-
market-untapped-potential-global-investment/.
 118. Louise Bleach, How Kenya’s Mobile Apps Are Changing the Face of Africa, THE
HUFFINGTON POST: THE BLOG (July 11, 2014, 7:41 AM), http://www.huffingtonpost.com/
fueled/how-kenyas-mobile-apps-ar_b_5577233.html.
 119. Seth Berkley, How Cell Phones Are Transforming Health Care in Africa, MIT TECH.
REV. (Sept. 12, 2013), available at http://www.technologyreview.com/view/519041/how-cell-
phones-are-transforming-health-care-in-africa/.
 120. OluwaBusayo Sotunde, 10 Apps That Are Reshaping Healthcare In Africa,
VENTURES AFRICA (Nov. 23, 2014), available at http://www.ventures-africa.com/2014/11/10-
apps-that-are-reshaping-healthcare-in-africa/.
121. Id.
122. Jessica L. Watterson et al., Using mHealth to Improve Usage of Antenatal Care, 
Postnatal Care, and Immunization: A Systematic Review of the Literature, 15 BIOMED RES.
INT’L (Jan. 22, 2015), http://www.hindawi.com/journals/bmri/2015/153402/
 123. Darrell West, How Mobile Devices Are Transforming Healthcare, ISSUES IN TECH.
INNOVATION (May 2012), available at http://www.brookings.edu/~/media/research/files/papers/
2012/5/22%20mobile%20health%20west/22%20mobile%20health%20west. 
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promote the sharing of personal medical data. 
And, just like chronic disease patients are most likely to be major 
beneficiaries in the growth of mHealth, and patient monitoring 
applications, particularly those in underserved markets and countries, 
so too, the growth of patient oriented social media sites are likely to 
particularly help and benefit the growing population of patients with 
chronic diseases and their friends, family, and loved ones.124,125 Given 
all this African market is prime for the introduction of the middleware 
described herein to support the nascent but growing mHealth 
infrastructure. Efforts should be taken here before stakeholders 
become too entrenched in their own non-standardized and 
unencrypted systems. 
III. PATIENT ORIENTED SOCIAL MEDIA SITES
Patient Oriented Social Media Sites (POSOMS) are social media 
networks, i.e., public and private compilations of interconnected 
webpages, where patients with similar diseases and/or conditions can 
network. This networking differs substantially from more mainstream 
sites like Facebook126 and Ello127 in that participants are not seeking 
out friends but rather useful and relevant information relating to their 
diseases.128
In this networking, patients (often banking on reciprocity from 
fellow patients129 and related individuals) can use, for example, 
associated tools and forums to help and inform each other with regard 
to their disease condition. This help can include sharing physician 
suggestions and rankings, as well as empirical, experimental, 
experiential, and anecdotal data related to drugs, therapies, side 
effects, and their referent diseases in general. This sharing of 
information has been found to be helpful both for the receiving 
community and also the individual sharing the information.130
 124. Hamid Pousti et al., Exploring the Role of Social Media in Chronic Care 
Management: A Sociomaterial Approach, 446 IFIP ADVANCES INFO. COMM. TECH. 163, 170-81 
(2014).
 125. Adam D. Farmer et al., Social Networking Sites: A Novel Portal for Communication,
85 POSTGRADUATE MED. J. 455, 456-58 (2009). 
 126. FACEBOOK, www.facebook.com (last visited Oct. 31, 2015). 
 127. ELLO, https://ello.co/ (last visited Oct. 31, 2015). 
 128. Nima Kordzadeh et al., A Multilevel Investigation of Participation Within Virtual 
Health Communities, 34 COMMC’NS OF THE ASS’N FOR INFO. SYSTEMS 493, 493, 505-06 
(2014).
 129. Id. at 495. 
 130. Jeana H. Frost & Michael P. Massagli, Social Uses of Personal Health Information 
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These sites, more so than standard social networking sites, also 
provide often much-need emotional support from empathetic 
individuals who appreciate the situation.131 These sites also allow 
patients to collectively check up on and/or validate potentially useful 
or damaging claims and statements related to their disease 
management;132 this collaborative filtering may help protect patients 
from all the disinformation online.133
In terms of patients managing their own diseases, many of these 
sites provide users with proprietary symptom management tools, 
medical management tools, databases of drugs and diagnostic-related 
tools, among others, each used by members of the sites to varying 
degrees.134 In some instances, patients can even employ these tools in 
their everyday interactions with their health care providers.135
Moreover, studies suggest that whereas particularly younger kids 
and teenage patients are unlikely to communicate regarding their 
disease in standard social media forums like Facebook and Twitter,136
they may be more likely to do so in these specialized forums. As 
such, these particular forums present a particularly important social 
media safe haven for these patients. This is also the case for severely 
ill patients who might not have any other regular interactions with 
peers.137
These sites include Patientslikeme.com,138 CureTogether.com,139
CarePages.com,140 HealthUnlocked.com,141 Smart Patients.com,142
Within PatientsLikeMe, an Online Patient Community: What Can Happen When Patients Have 
Access to One Another’s Data, 10 J. MED. INTERNET RES. (Aug. 25, 2008); Paul Wicks et al., 
Sharing Health Data for Better Outcomes on PatientsLikeMe, 12 J. MED. INTERNET RES. (June 
14, 2010). 
 131. Kordzadeh et al., supra note 128, at 505-07. 
 132. Jeremy A. Greene et al., Online Social Networking by Patients with Diabetes: A 
Qualitative Evaluation of Communication With Facebook, 26 J. OF GEN. INTERNAL MED. 287, 
288 (2011). 
 133. Gunther Eysenbach, Medicine 2.0: Social Networking, Collaboration, Participation, 
Apomediation, and Openness, 10 J. MED. INTERNET RES. (Aug. 25, 2008). 
 134. Wicks et al., supra note 130. 
 135. Id.
 136. Maja Van Der Velden & Khaled El Emam, “Not All My Friends Need to Know”: A 
Qualitative Study of Teenage Patients, Privacy, and Social Media, 20 J. AM. MED.
INFORMATICS ASS’N 16, 20 (2013). 
 137. See Kate Khair et al., Social Networking For Adolescents With Severe Haemophilia,
18 HAEMOPHILIA 290, 294 (2012). 
 138. PATIENTSLIKEME, http://www.patientslikeme.com/ (last visited Oct. 31, 2015). 
 139. CURETOGETHER, http://curetogether.com/ (last visited Oct. 31, 2015). 
 140. CAREPAGES, https://www.carepages.com/ (last visited Oct. 31, 2015). 
 141. HEALTHUNLOCKED, https://healthunlocked.com/ (last visited Oct. 31, 2015). 
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UPOPOLIS (“a private online social network available exclusively to 
pediatric patients in hospitals and care facilities”)143 and others,144
although not all are as democratic or as friendly as they make 
themselves out to be. It is not clear how many of the contributing 
patients and relatives appreciate and understand this.145
Some, like HealthTap.com,146 are more app than social media, 
but nevertheless provide many of the same services to patients. 
Others, like Ginger.io are narrowly presented as only for collecting 
patient crowdsourced data.147 Still others, while providing many of 
the support services, are focused solely on collecting data, not for 
pharmaceutical and health-related studies, but for marketers to these 
patient communities.148 And others like Treato.com, are not online 
communities in and of themselves, but rather, scrapers that search the 
Internet for related data and information.149
Overall the trend toward a growing number of patient oriented 
social media sites seems like a positive development for patients and 
their friends and families, who even in well-served markets might 
otherwise not have sufficient and/or necessary access to support 
groups and/or healthcare professionals on a regular basis. Even 
finding medical professionals specializing in a particular disease, an 
exercise that can sometimes be difficult, particularly for patients just 
recently informed of their condition, can be facilitated in these 
forums. Additionally POSOMS are important tools for patients to 
simply collect catalogue and disseminate information about their 
disease; oftentimes particularly rare diseases suffer from a lack of 
accessible information.150  POSOMS can be the only lay source of 
reliable information. 
Moreover, these sites have the potential to provide all patients 
 142. SMART PATIENTS, https://www.smartpatients.com/ (last visited Oct. 31, 2015). 
 143. UROPOLIS, https://www.upopolis.com/ (last visited Oct. 31, 2015). 
 144. See, e.g., Grazia Orizio et al., The World of e-Patients: A Content Analysis of Online 
Social Networks Focusing on Diseases.” 16 TELEMEDICINE & E-HEALTH 1060, 1062 (2010), for 
a relatively early and lengthy list. 
 145. See Deborah Lupton, The Commodification of Patient Opinion: The Digital Patient 
Experience Economy in the Age of Big Data, 36 SOC. HEALTH & ILLNESS 856, 866 (2014). 
 146. HEALTHTAP, https://www.healthtap.com/ (last visited Oct. 31, 2015). 
 147. GINGER.IO, https://ginger.io/ (last visited Oct. 31, 2015). 
 148. ALLIANCE HEALTH, https://www.alliancehealth.com/ (last visited Oct. 31, 2015). 
 149. TREATO, http://treato.com/ (last visited Oct. 31, 2015). 
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Collaboration, 6 J. COMMC’N IN HEALTHCARE 71 (2013). 
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with data to make better informed decisions about their health151 and/
or to share with similarly afflicted individuals other important and 
relevant information about care and disease management.152, 153 And, 
in general, these more informed patients can be more responsible for 
their health and make more rational decisions.154  This combined with 
perhaps the need for fewer in-person visits can relieve strain on a 
healthcare system.155
Additionally, social relationships, be they online or in person 
(although some have suggested that online networks may erode 
otherwise useful real-world networks156), have been shown to have 
positive effects on a patient’s condition disease management157 and 
disease outcome.158,159 Conversely, the lack and/or loss of a social 
network have been known to be detrimental.160, 161 These sites may 
also provide the necessary incentives to mitigate attrition from the 
self-monitoring apps described above.162,163 Further these sites and 
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associated social networks allow patients to develop positive self-
images in relation to their disease.164
Patient oriented social media sites can also be particularly 
powerful for the underserved. In many instances socially and/or 
culturally disadvantaged patients may have trouble following and 
interacting with medical professionals in an office setting, but may 
find it easier to interact online in a more relaxed setting with 
computing tools that provide quick translation or definitions of 
complicated jargon. 
A.  Concerns With Patient Oriented Social Media Sites 
While POSOMS have been around for at least a decade, there 
remain a number of interesting heretofore unanswered research 
questions, including: (1) how do these networks affect health-related 
decisions; (2) to what extent do different individuals on these 
networks influence patients, individually and collectively; (3) what is 
the role of a physician and other healthcare workers vis-à-vis these 
sites; and (4) how does activity on these sites affect patient-health-
worker relationships offsite?165 Additionally, are patients being 
exploited by these sites or others trolling the sites?166
1.  Patient Privacy 
A particularly pertinent issue relates to patient privacy on these 
websites.167  Patients on these sites are encouraged to share their 
data.168, 169 While privacy is a general concern online, and particularly 
in social media, where simply tracking someone’s seemingly benign 
“likes” and/or status updates can identify and characterize her,170
 163. But see Cory A. Heidelberger et al., Online Health Social Networks and Patient 
Health Decision Behavior: A Research Agenda, IEEE COMPUTER SOCIETY (2011), https://
www.computer.org/csdl/proceedings/hicss/2011/4282/00/07-05-09.pdf.
 164. See Greene et al., supra note 132. 
 165. Heidelberger et al., supra note 163. 
 166. Natasha Singer, When Patients Meet Online, Are There Side Effects?, N.Y. TIMES
(May 29, 2010), available at http://www.nytimes.com/2010/05/30/business/30stream.html?_
r=0.
167. Jingquan Li, Privacy Policies for Health Social Networking Sites, 20 J. AM. MED.
INFORMATICS ASS’N 704 (2013).
 168. Deborah Lupton, The Commodification of Patient Opinion: The Digital Patient 
Experience Economy in the Age of Big Data, 36 SOCIOLOGY HEALTH & ILLNESS 856 (2014).
 169. Katherine C. Chretien & Terry Kind, Social Media and Clinical Care Ethical, 
Professional, and Social Implications, 127 CIRCULATION 1413 (2013).
 170. Golnoosh Farnadi et al., Recognising Personality Traits Using Facebook Status 
Updates, in Proceedings of the Workshop on Computational Personality Recognition 
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these concerns are exacerbated in POSOMS where a patient’s guard 
may be down in a seemingly safe environment171 and where they 
might tend to share more personal and health-related information than 
they might otherwise on non-health-related websites. It takes very 
little information to deanonymize someone’s online profile, as was 
recently shown when Netflix’s anonymous database of movie 
preferences was deanonymized when the provided anonymous 
information was cross-referenced with the IMDB database.172
Similarly, one’s anonymous POSOM profile may be deanonoymized 
by comparing it to, say, a database of Facebook profiles. 
There is also the possibility that a patient’s disclosure on these 
sites, or even simply her membership on the site, could affect her or 
her close families’ ability to obtain health and/or life insurance a job 
and a relationship.173,174 It remains unclear as to how the Genetic 
Information Nondiscrimination Act (GINA) would prevent employers 
and health care providers from using information freely shared on 
these sites – even anonymous sharing that might be relatively easily 
deanonymized.175 SNOPA, the Social Networking Online Protection 
Act, was an effort to plug some of these gaps. It has so far been 
unable to become law.176
2.  Defamation 
Many patients feel that these sites are safe havens for 
communicating otherwise sensitive and stigmatizing information.177
This feeling of a safe haven combined with the desire to share 
(WCPR13) at the 7th International AAAI Conference on Weblogs and Social Media (2013); 
Michal Kosinski et al., Private Traits and Attributes are Predictable From Digital Records of 
Human Behavior, 110 PROC. NAT’L ACAD. SCI. 5802 (2013); Yoram Bachrach et al., 
Personality and Patterns of Facebook Usage, in Proceedings of the 3rd Annual ACM Web 
Science Conference (2012); Dejan Markovikj et al., Mining Facebook Data for Predictive 
Personality Modeling, in Proceedings of the 7th International AAAI Conference on Weblogs 
and Social Media (2013). 
 171. See Li, supra note 157. 
 172. Arvind Narayanan & Vitaly Shmatikov, Robust De-Anonymization of Large Sparse 
Datasets, in 2008 IEEE Symposium on Security and Privacy (2008). 
 173. See Van Der Velden & El Emam, supra note 136. 
174. Daniel J. Solove, The End of Privacy?, 299 SCI. AM. 100 (2008).
 175. Sandra Soo-Jin Lee & Emily Borgelt, Protecting Posted Genes: Social Networking 
and the Limits of GINA, 14 AM. J. BIOETHICS 32 (2014). 
 176. Social Networking Online Protection Act, H.R. 5050, 112th Cong. (2012); Social 
Networking Online Protection Act, H.R. 537, 113th Cong. (2013). These acts died in committee, 
see, e.g., https://www.govtrack.us/congress/bills/112/hr5050. 
 177. Jacqueline L. Bender et al., Seeking Support on Facebook: A Content Analysis of 
Breast Cancer Groups, 13 J. MED. INTERNET RES., Jan.–Mar. 2011. 
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relevant information online described above can also lead to 
actionable defamation of doctors and health care workers.178 As per 
the Restatement (Second) of Torts (1977), “[t]o create liability for 
defamation there must be: (a) a false and defamatory statement 
concerning another; (b) an unprivileged publication to a third party; 
(c) fault amounting at least to negligence on the part of the publisher 
[with respect to the act of publication]; and  (d) either actionability of 
the statement irrespective of special harm or the existence of special 
harm caused by the publication.”179
Further, “[a] communication is defamatory if it tends so to harm 
the reputation of another as to lower him in the estimation of the 
community or to deter third persons from associating or dealing with 
him.”180 Most social media sites, including POSOMS, can be 
described as public forums, and like their offline counterparts, 
members have to be cognizant of the limitations of their speech. 
Members on POSOMS face even greater dangers than standard 
run-of-the-mill social media sites which themselves suffer from the 
lack of fail safes (e.g. time and editors) that typically protect 
individuals in offline public forums from defaming and/or libeling 
individuals.181 Moreover, patients may feel that the information that 
they are presenting regarding a healthcare worker will help other 
patients and as such might be more likely to post something 
defamatory as a result than on other social media sites. Note that 
while defamation can be found by a court even when the defamatory 
statement is phrased as an option, many states provide laws and anti-
SLAPP statutes that protect some forms of speech when the speech 
was without malice and when it was believed to be true.182
Even pharmaceutical companies can sue for libel and/or 
defamation for online defamatory and/or libelous comments, a likely 
occurrence on these sites where patients may be advising other 
 178. Brian Chou and Walt Mayo, ‘I was Dissed on Angie’s List,’ REVIEW OF OPTOMETRY
(April 15, 2009),  available at https://www.reviewofoptometry.com/article/i-was-dissed-on-
angies-list; Nicolas P. Terry, Fear of Facebook: Private Ordering of Social Media Incurred by
Healthcare Providers, 90 NEB. L. REV. 703 (2012). 
 179. RESTATEMENT (SECOND) OF TORTS § 558 (1977). 
 180. Id. § 559. 
 181. Ian Burrell, Libel Cases Prompted by Social Media Posts Rise 300% in a Year,
INDEP. (Oct. 19, 2014), available at http://www.independent.co.uk/news/uk/home-news/libel-
cases-prompted-by-social-media-posts-rise-300-in-a-year-9805004.html.
 182. Elec. Frontier Found., Online Defamation Law, ELECTRONIC FRONTIER
FOUNDOUNDATION available at,  https://www.eff.org/issues/bloggers/legal/liability/defamation. 
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patients. 183However, at least in the United States, under the 
Communications Decency Act of 1996, the social media network 
itself is likely immune from defamations made by members or third 
parties,184 leaving behind few deep pockets to sue.185
In some instances where it might be obvious that the putatively 
defamatory comment is an opinion, the individual publishing the 
opinion may also not be liable.186 Thus, when “a “reasonable reader 
would not view the blanket, unexplained statements at issue as 
“facts,” [rather...] subjective speculation’ or “merely rhetorical 
hyperbole,” there may be no liability unless the plaintiff proves “that 
a statement is factually based and thus capable of a defamatory 
meaning.”187
3.  Abuse Of Trust 
Patient-oriented social media sites may also present 
opportunities for others to prey on patients and their families, for 
example, by individuals misrepresenting their medical credentials, or 
lack thereof.188 This can also include doctors or other healthcare 
workers who are looking for individuals to sign up for clinical studies. 
Rather than going through standard channels, doctors can come to 
these social media sites to find a consolidated and interested 
population with disclosed medical histories and conditions so that 
they can find the best-suited individuals for their trials. A number of 
clinical trials have already been staffed through contacting patients 
via POSOMS.189 And while the FDA has specific rules for trial 
 183. Nanoviricides, Inc. v. Seeking Alpha, Inc., No. 151908/2014, 2014 WL 2930753 
(N.Y. Sup. June 26, 2014); Biomatrix Corp., et al. v. Costanzo, et al., Docket No. BER-L-670-00
(Superior Court of New Jersey, Bergen County); Eric Niiler, Internet Chat Damages 
Biotechnology Stocks, NATURE BIOTECHNOLOGY (2000), available at http://www.nature.com/
nbt/journal/v18/n10/full/nbt1000_1030b.html; Aaron Elstein, Judge Rules Online Postings 
About Biomatrix Were Libel, WALL ST. J. (Aug. 3, 2000), available at http://www.wsj.com/
articles/SB965239740373615064.
184. E.g., Zeran v. America Online, Inc., 129 F.3d 327, 330 (4th Cir. 1997), cert. denied,
524 U.S. 937 (1998) (ruling that Section 230 of the Communications Decency Act “creates a 
federal immunity to any cause of action that would make service providers liable for 
information originating with a third-party user of the service.”); see also Barrett v. Rosenthal, 40 
Cal. 4th 33 (2006). 
 185. 47 U.S.C. § 230(c)(1) (2012) (“No provider or user of an interactive computer service 
shall be treated as the publisher or speaker of any information provided by another information 
content provider.”). 
 186. Doe v. Cahill, 884 A.2d 451, 466 (Del. 2005). 
 187. Id. at 467-68 n.78. 
188. Chretien & Kind, supra note 169.
 189. Melanie Swan, Emerging Patient-Driven Health Care Models: An Examination of 
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recruitment, they are not geared to online recruitment,190 and may or 
may not clearly be applied.191
Even worse, snake-oil salesmen might present themselves as 
legitimate pharmaceutical representatives or medical professionals to 
sell useless or even harmful concoctions to the unassuming public 
within what seems to them, to be a protected environment.192
In general, doctors and others trolling for bodies for their trials 
should not do so anonymously, particularly when their perceived lack 
of duty to someone else’s patient might result in them choosing 
individuals who are best for the trial, although not necessarily 
pointing out trials that are best for the individuals. Further, patients, 
who might otherwise not sign up for clinical trials unless they were 
presented to them by their trusted physician, may sign up for trials 
that might not be in their best interests when approached online. In 
some instances, a patient may sign up for what they perceive to be a 
legitimate IRB approved trial, when in reality it is an ad hoc trial by 
an unregulated body. 
Additionally, concerns should be raised given that 
pharmaceutical representatives or their paid agents can promote, 
under the anonymity provided by the internet, their product, promote 
off label use, disparage competing products, and use other marketing 
tactics without disclosing their conflicts of interest. Even overtly, 
patients may be influenced by directed marketing to choose one drug 
over another. Pharmaceutical companies have made substantial efforts 
in these areas, including, for example, conversational marketing (i.e., 
to make online friends and then turn those friends into customers) and 
efforts to create online threads lead by peer influencers.193 In some 
instances, patients are not even interacting with real individuals but 
Health Social Networks, Consumer Personalized Medicine and Quantified Self-Tracking, 6 
INT’L J. ENVTL RES. & PUBLIC HEALTH 492 (2009).
 190. Jim Gearheart, Clinical Trial Recruitment Using Social Media is Growing, 5 
QUORUM REVIEW IRB (Mar. 5, 2015), available at http://www.quorumreview.com/blog/2015/
03/05/clinical-trial-recruitment-social-media-growing/.
 191. Kristen Snipes, Rho Regulatory Considerations for Using Social and Digital Media in 
Clinical Trial Patient Recruitment, CLINICAL INFORMATICS NEWS (May 26, 2015), available at
http://www.clinicalinformaticsnews.com/2015/3/26/regulatory-considerations-using-social-
digital-media-clinical-trial-patient-recruitment.html.
192. Bradford W. Hesse et al., Social Participation in Health 2.0, 43 COMPUTER 45 
(2010).
 193. Manon Niquette, The Exploitation of “Sicko-Chatting” by the Pharmaceutical 
Industry: A Strategy for the Normalization of Drug Use, SCIENTIFIC PUBLICATIONS OF THE 
HUMANITIES AND SOCIAL SCIENCES UNIVERSITY OF LILLE (2013), available at http://hal.univ-
lille3.fr/hal-00835818v2.
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rather artificial intelligence software aimed at creating new 
customers.194 The extent of pharmaceutical representation on these 
sites is unknown, as is the extent that pharmaceuticals promote 
openly, or using sock puppets,195 their products.196
Finally, the aggregation of lay-minded patients on these website 
can  influence policy, regulation and crowdsourced funded research 
both positively, and potentially negatively, if the lay-minded patients 
are taken advantage of; each privately run POSOM potentially is its 
own institution with its “own leadership, goals and agenda.”197
a.  Regulation Of Patient Oriented Social Media Sites 
All these concerns notwithstanding, the FDA has been loath to 
substantively regulate social media in general198 and specifically as it 
relates to pharmaceutical advertising.199 Social media is actually 
already subject to some diverse sets of regulation. For example, on 
standard social media sites, many non-pharmaceutical ads are 
regulated via the FTC, financial communications with customers via 
social media is regulated by the Financial Industry Regulatory 
Authority, and the National Labor Relations Board provides 
regulation regarding employer restrictions on access to social 
media.200
However, like their efforts to regulate mobile medical 
applications as devices, the FDA should similarly regulate broader 
aspects of social media, particularly when those aspects of social 
media as designed specifically for use in healthcare and health 
delivery. While the FDA held public hearings in 2009 on issues 
 194. A similar example can be found from disclosures from the Ashley Madison website. 
See, e.g., Annalee Newitz, How Ashley Madison Hid Its Fembot Con From Users and 
Investigators, GIZMODO (Sept. 8, 2015), available at http://gizmodo.com/how-ashley-madison-
hid-its-fembot-con-from-users-and-in-1728410265.
 195. Chelsea Peters, Whole Foods, Unwholesome Practices: Will Sock Puppeteers Be Held 
Accountable for Pseudonymous Web Postings, 5 SHIDLER J.L. COM. & TECH. 4, 5 (2008). 
 196. Greene et al., supra note 132. 
 197. Swan, supra note 189.
 198. Venkatesh Shankar & Jiaoyang (Krista) Li, Leveraging Social Media in the 
Pharmaceutical Industry, in INNOVATION AND MARKETING IN THE PHARMACEUTICAL
INDUSTRY 477 (Min Ding et al. eds., 2014). 
 199. U.S. Food and Drug Admin., For Industry: Using Social Media,  ABOUT FDA (Oct.
29, 2014), available at http://www.fda.gov/AboutFDA/CentersOffices/
OfficeofMedicalProductsandTobacco/CDER/ucm397791.htm.
 200. Jon Poracro, Social Media Laws and Regulations You Should Know, METIA (Aug. 26, 
2011), available at http://www.metia.com/seattle/john-porcaro/2011/08/social-media-laws-and-
regulations-you-should-know/.
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relating to promotional speech through social media,201 it has only 
very recently released very limited guidance relating to discussing 
pharmaceuticals on social media sites. In the interim, while the FDA’s 
Office of Prescription Drug Promotion, formerly known as the 
Division of Drug Marketing, Advertising, and Communications, 
whose goal is to: 
To protect the public health by assuring prescription drug 
information is truthful, balanced and accurately communicated. 
This is accomplished through a comprehensive surveillance, 
enforcement and education program, and by fostering better 
communication of labeling and promotional information to both 
healthcare professionals and consumers.202
In fact, the FDA has sent out only one regulatory action letter to 
a pharmaceutical company where social media was the basis for the 
offensive action in the years between 2008 and 2013.203 The only real 
substantive guidance provided by the FDA in relation to social media 
sites relates to correcting false information online – in short there is 
no duty to correct online misinformation and traditionally, 
pharmaceuticals have steered clear of correcting misinformation for 
fear of backlash from the FDA. 204The new guidance however also 
allows companies the right to correct misinformation, provided that 
the correction is “relevant and responsive,” “limited and tailored,” 
“non-promotional,” and “accurate.”205 With this burden, it is unclear 
how many pharmaceutical companies will take the opportunity to 
 201. U.S. Food and Drug Admin., Public Hearing on Promotion of FDA-Regulated 
Medical Products Using the Internet and Social Media Tools, ABOUT FDA (Nov. 27, 2015), 
available at http://www.fda.gov/AboutFDA/CentersOffices/
OfficeofMedicalProductsandTobacco/CDER/ucm184250.htm.
 202. U.S. Food and Drug Admin., The Office of Prescription Drug Promotion, ABOUT
FDA (Oct. 23, 2015) available at http://www.fda.gov/AboutFDA/CentersOffices/
OfficeofMedicalProductsandTobacco/CDER/ucm090142.htm.
 203. Mark S. Senak, FDA Communications Oversight in a Digital Era 2008-2013,
EYEONFDA (Apr. 2013), available at http://www.eyeonfda.com/wp-content/uploads/2013/03/
FDA-Communications-Oversight-in-a-Digital-Era1.
204. See, e.g., Policy and Medicine, FDA Social Media Guidance: Correcting Independent 
Third-Party Misinformation About Prescription Drugs and Medical Devices, POLICY AND 
MEDICINE (June 18, 2014), available  at http://www.policymed.com/2014/06/fda-social-media-
guidance-correcting-independent-third-party-misinformation-about-prescription-drugs-and-
medical-devices.html (“Previously, companies have struggled with the best way to approach this 
type of online misinformation. FDA’s Guidance provides clarity”). 
 205. U.S. Food & Drug Admin., Guidance for Industry: Internet/Social Media Platforms: 
Correcting Independent Third-Party Misinformation About Prescription Drugs and Medical 
Devices, U.S. FOOD AND DRUG ADMIN. (June 2014), http://www.fda.gov/downloads/drugs/
guidancecomplianceregulatoryinformation/guidances/ucm401079.pdf. 
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correct misinformation when they are legally safer to not say 
anything. Note: there is also guidance for pharmaceuticals with 
relation to microblogging.206
Other governmental agencies are also interested in some aspects 
of POSOMS, including for example the FTC’s interest in the patient 
privacy aspects related to patient data that is collected and catalogued 
on many of these sites.207
The lack of FDA and other governmental oversight of POSOMS 
will become increasingly problematic as both industry208 and 
regulators themselves209 look to POSOMS as sources of 
crowdsourced, user generated data for use in research and 
development of medicine and other health-related technologies. 
b.  Patient Oriented Social Media Sites And Data 
Creation And Collection 
Obviously, POSOMS do not only help patients and their 
families, other stakeholders benefit substantially from the data that 
can be mined from these websites. Patients on these sites should be 
wary: “When something online is free, you’re not the customer, 
you’re the product.”210 Patientslikeme.com, and presumably other 
similar social media websites make money by selling personal and 
potentially private information.211,212 Even when they are not outright 
206. Id.
 207. Fed. Trade Comm’n, FTC Announces Agenda, Panelists for Upcoming Seminar on 
Privacy Implications of Consumer Generated and Controlled Health Data, FED. TRADE
COMM’N PRESS RELEASES (May 1, 2014), available at http://www.ftc.gov/news-events/press-
releases/2014/05/ftc-announces-agenda-panelists-upcoming-seminar-privacy.
 208. Jennifer Levin, AstraZeneca and PatientsLikeMe Announce Global Research 
Collaboration, FIERCEBIOTECH (April 14, 2015), available at http://www.fiercebiotech.com/
press-releases/astrazeneca-and-patientslikeme-announce-global-research-collaboration.
 209. Thomas Sullivan, PatientsLikeMe Teams With FDA To Explore Patient-Reported 
Adverse Events, POLICY AND MEDICINE (July 9, 2015), available at http://www.policymed.com/
2015/07/patientslikeme-teams-with-fda-to-explore-patient-reported-adverse-events.html.
 210. Jonathan Zittrain, The Future of the Internet and How to Stop It, HARVARD LAW
BLOGS (Mar. 21, 2012), http://blogs.law.harvard.edu/futureoftheinternet/2012/03/21/meme-
patrol-when-something-online-is-free-youre-not-the-customer-youre-the-product/.
 211. PatientsLikeMe, Does PatientsLikeMe Sell My Information?, PATIENTSLIKEME
(2014), available at https://support.patientslikeme.com/hc/en-us/articles/201245770-Does-
PatientsLikeMe-sell-my-information- (“The data and text you enter in and around the shared 
parts of the site (e.g., on your profile, in the forum, symptom or treatment reports) may be 
shared or sold in aggregate to partners.”). 
 212. Jim Edwards, PatientsLikeMe is More Villain than Victim in Patient Data 
“Scrapping” Scandal,  CBS MONEYWATCH (Oct. 19, 2010), available at http://
www.cbsnews.com/news/patientslikeme-is-more-villain-than-victim-in-patient-data-scraping-
scandal/ (“Here’s what type of data PatientsLikeMe scrapes from its own site for its clients: 
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selling data, other companies may be scraping (i.e., “collecting online 
data from social media and other Web sites in the form of 
unstructured text . . . also known as site scraping, web harvesting and 
web data extraction”)213 personal data from these sites.214
POSOMs are incentivized to get as many patients as possible to 
sign up and eventually even disclose their health-related data, as they, 
their corporate consumers and the patients themselves can benefit 
from the network effects resulting from greater participants.215
PatientsLikeMe, founded in 2004, is one of the more popular 
patient oriented social media sites.  With more than a quarter of a 
million members and 2000 health conditions, the site was noted in 
2007 as a company that will change the world.216 The site is 
configured to allow patients with similar diseases connect with their 
peers to share information. And like many of the mHealth apps 
described above, PatientsLikeMe.com and other similar sites 
empower patients to learn more and do more about their health 
condition.
This patient empowerment is part of a general trend that includes 
crowdsourcing, citizen science.217 uBiome (a citizen science 
startup)218 and other forms of participant led research — sometimes 
known as prosumption (the simultaneous production and consumption 
of information)219—  can empower the patient, subject, or non-health 
Condition/disease information, including diagnosis date, first symptom information, and family 
history; Treatment regimens, including treatment start dates, stop dates, dosages, and side 
effects; Symptoms experienced, including severity and duration; Laboratory results (e.g. CD-4 
count, Viral Load); Biographical information, including photo, bio, gender, age, location (city, 
state & country), and general notes; Genetic information, including information on individual 
genes and/or entire genetic scans”). 
213. Bogdan Batrinca & Philip C. Treleaven, Social Media Analytics: A Survey of 
Techniques, Tools and Platforms, 30 AI & SOC’Y 89 (2015).
 214. Julia Angwin & Steve Stecklow, ‘Scrapers’ Dig Deep for Data on Web, WALL ST. J.
(Oct. 12, 2010), available at http://www.wsj.com/news/articles/
SB10001424052748703358504575544381288117888?mod=WSJ_0_0_WP_2715_
RIGHTTopCarousel_1&mg=reno64wsj&url=http%3A//online.wsj.com/article/
SB10001424052748703358504575544381288117888.html%3Fmod%3DWSJ_0_0_WP_2715_
RIGHTTopCarousel_1.
 215. Frost & Massagli, supra note 130. 
 216. Erick Schonfeld & Chris Morrison, The Next Disruptors, CNN MONEY (Aug. 22, 
2007), available at http://money.cnn.com/magazines/business2/business2_archive/2007/09/01/
100169862/index.htm.
 217. Rick Bonney et al., Citizen Science: A Developing Tool for Expanding Science 
Knowledge and Scientific Literacy, 59 BIOSCIENCE 977 (2009). 
 218. UBIOME, http://ubiome.com/ (last visited Nov. 1, 2015). 
 219. David Beer & Roger Burrows, Consumption, Prosumption and Participatory Web 
Cultures: An Introduction, 10 J. CONSUMER CULTURE 3 (2010); George Ritzer & Nathan 
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practitioner stakeholder to partially direct, control or simply have a 
greater degree of input in the analysis than they otherwise mite via the 
classical investigator led research (ILR) paradigm.220
Some have argued that these non-commercial, disease-oriented, 
and patient-controlled studies provide a greater likelihood of resulting 
in real actionable changes for patients and their families.  
Additionally, without the profit limitations of large drug corporations, 
patient-directed research allows for research in even unprofitable or 
otherwise marginalized areas. 
In fact, the use of POSOMS promises to provide scientists with 
new and novel ways of collecting heretofore hard-to-collect data 
related to diseases, including for example, otherwise very expensive, 
hard-to-find, and hard-to-collect data on off-label usage of 
pharmaceuticals.221 This is not necessarily a bad thing.222 Some would 
argue that collecting data directly from patients, often in real time as 
they interact with the social media site, results in fewer concerns 
about the veracity of data,223 particularly as a result of memory 
bias.224
Moreover, the use of patient reported data, particularly from 
POSOMS, can make expensive and time consuming off-label and 
new-use studies for existing drugs feasible.225 POSOMS have also 
been helpful in locating otherwise lost patients in long-term 
longitudinal studies.226
There are some downsides to patients collectively becoming 
more involved in their research, particularly outside of normal 
Jurgenson, Production, Consumption, Prosumption: The Nature of Capitalism in the Age of the 
Digital “Prosumer”, 10 J. CONSUMER CULTURE 13 (2010). 
 220. Effy Vayena & John Tasioulas, The Ethics of Participant-Led Biomedical Research,
31 NATURE BIOTECHNOLOGY 786 (2013). 
 221. Jeana Frost et al., Patient-Reported Outcomes as a Source of Evidence in Off-Label 
Prescribing: Analysis of Data From PatientsLikeMe, 13 J. MED. INTERNET RES., Jan.—Mar. 
2011.
 222. See Dina Fine Maron, Your Medical Records May Unlock Disease Secrets for All,
SCI. AM. (August 6, 2015), available at http://www.scientificamerican.com/article/your-
medical-records-may-unlock-disease-secrets-for-all/.
 223. Paul Wicks et al., Accelerated Clinical Discovery Using Self-Reported Patient Data 
Collected Online and a Patient-Matching Algorithm, 29 NATURE BIOTECHNOLOGY 411 (2011). 
 224. Jeana H. Frost, The Case for Using Social Media to Aggregate Patient Experiences 
with Off-Label Prescriptions, 11 EXPERT REV. PHARMACOECONOMICS & OUTCOMES RESEARCH
371 (2011). 
 225. Frost, supra note 221. 
 226. Allison Cook Reaves & Diana W. Bianchi, The Role of Social Networking Sites in 
Medical Genetics Research, 161 AM. J. MED. GENETICS PART A 951 (2013). 
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operating parameters: for example, in one case a large cohort from a 
study colluded on Patientslikeme.com to determine who was 
receiving a placebo and who was receiving the actual drug over the 
course of a double-blind study, this sort of revelation can seriously 
harm the integrity of an expensive drug study.227
Other concerns include issues of selection bias (data population 
does not accurately reflect the actual broader patient population), 
confounding (misleading associations resulting from, for example, a 
third unrelated piece of information) and information bias (related to 
systematic errors associated with the collection of the data), resulting 
with, at minimum, that patient provided data collected through 
POSOMS out to be read and interpreted with a certain degree of 
caution.228  Moreover, patient-led research lacks many of the built-in 
checks and balances of institutional-based research. For example, 
patient-led research typically does not carry the same ethical 
oversight; institutional review boards (IRBs) are typically lacking or 
privately financed in citizen science endeavors. (Some have also 
suggested that the same model that provides for patient led research, 
could also provide for patient-led or otherwise crowdsourced ethical 
review boards.229)
Further, patient led research includes other ethical and scientific 
concerns including, lack of state recognition and support, issues 
related to the veracity and reliability of self-reported results,230
general concerns with self-experimentation, inability to appreciate the 
risks of their own research, and the general blurring of the lines 
between researchers, subjects and sponsors, potentially a lack of 
openness and transparency and lack of informed consent.231 Some 
have further argued that this patient-led “disobedience” against the 
institutionalized research system, while enabling rapid dissemination 
of research results and perhaps a greater degree of self-knowledge, 
nevertheless wades into ethically murky areas by short-circuiting 
227. Virginia Hughes, Social Storm: The Drug Industry is Struggling to Find Ways of 
Engaging with Consumers on Social Media, 33 NATURE BIOTECHNOLOGY 14 (2015).
 228. A. Cecile JW Janssens & Peter Kraft, Research Conducted Using Data Obtained 
Through Online Communities: Ethical Implications of Methodological Limitations, 9 PLOS
MED. (2012). 
229. See, e.g., Melanie Swan, Scaling Crowdsourced Health Studies: The Emergence of a 
New Form of Contract Research Organization, 9 PERSONALIZED MED. 223 (2012). 
 230. Frost, supra note 221. 
 231. Effy Vayena, Opinion: Unconventional Standards, THE SCIENTIST (Mar. 13, 2013), 
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standard pathways to review ethical concerns as well as informed 
consent.232
c.  Suggestions For Regulation 
With nearly 300,000 members on Patientslikeme.com alone,233
not to mention the tens if not hundreds of other sites, actively policing 
these sites is not really feasible. 
Nevertheless, patient oriented social media sites need some sort 
of regulatory oversight, not least because they involve a captured, 
desperate, and perhaps naïve community that can be easily taken 
advantage of. 
As described above, concerns particularly come into play when 
patients are approached by health care workers or their doctors on 
these types of sites. These concerns are particularly apropos when 
these approaches are through thread initiators, individuals who tend to 
have substantial sway on these social media sites.234 While some 
might argue that these sorts of interactions are important to humanize 
the doctors and open up otherwise stifled channels,235 others are wary 
of inappropriate and/or illegal patient-doctor relationships,236, 237 with 
some setting some important ground rules for these types of 
relationships.238 In particular, social media interactions between 
doctors and patients raise these and other concerns: whether a 
doctor’s particular opinion in one of these forums, intended narrowly 
may be misconstrued in a broader sense; difficulties in maintaining 
patient and colleague privacy; and whether the relaxed atmosphere 
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may lead a professional to misrepresent science, medicine or their 
institutions or the nature of their degree and/or specialty. Nevertheless 
these sites remain practical additions to regular health care visits, with 
physician participation online most rewarding for underserved 
communities and geographically mobile patients.239
Other issues related to POSOMs relate generally to the 
generation and use of the patient and personal data on the websites. 
Who owns the data? Who is responsible for the accuracy of the 
patient’s data and any data presented to the patient through the 
website, other members (e.g., patients and family) participating on the 
website and/or third parties? Who can access the data? Who is 
responsible for protecting and validating the data?240
In contrast to MMAs, a technological solution may not be best. 
In fact, with enforced proper disclosures, many of the concerns raised 
become mute. The problem lies in enforcing that disclosure and/or 
educating the often naïve consumer. 
One solution might include a multi-tiered approach based on a 
certification that could be displayed on the websites’ homepages. 
Thus, whatever governmental agency or non-governmental group 
takes it upon themselves to police these sites, that group/agency 
would make it known immediately to all visitors whether or not the 
site is in compliance with best practices or not.  In addition to the 
certification mark, a concerted effort ought to be made to inform the 
doctors to educate their patients, if nothing else, to at least be wary 
and suspicious of their online interactions, even in their perceived 
safe environments of their online communities. 
To this end, the policing body would be developed, perhaps in 
conjunction with patient groups, industry groups and other related 
agencies. Importantly, a set of best practices for all aspects of running 
the website, taking into account the needs and concerns of all 
stakeholders could be developed. This would include best practices 
relating to health-care worker anonymity, anonymizing data, 
advertising, selling data, patient interactions, physician interactions, 
pharmaceutical industry interactions and other relevant areas of 
concern. For example, physicians should be required to be non-
anonymous with their credentials vetted. Similarly, pharmaceutical 
 239. Gemma Sinead Ryan, Online Social Networks for Patient Involvement and 
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companies and their agents would have to be clearly identified or risk 
being banned from the site. Perhaps something akin to Amazon’s 
Real Name Badge program in customer reviews.241 Additionally, 
patients should have to be fully informed in a clear and industry-wide 
consistent manner as to what happens to their data. Moreover, sites 
should employ the necessary technologies to prevent the wholesale 
scraping of data, as well as limiting non-member access to non-
privileged areas. 
Best practices would be suggested industry wide with 
certification seals from the oversight /policing group only provided to 
those websites that subscribe to all the best practices. Perhaps the 
same oversight/policing group could employ monitors to check up, 
unannounced, on a semi regular basis to review protocols, obtain data 
about problematic instances (e.g., an unidentified doctor, an 
individual masquerading as a doctor, defamation, or promotion of off-
label uses by pharmaceuticals) and confirm that the website dealt with 
these issues as per best practices and protocol. 
National and/or regional IRBs should also be created, not only 
would these be of value to many institutions that do not have the 
knowledgebase to create their own multidisciplinary IRBs, but also 
for citizen science resulting from patient oriented social media sites. 
Currently, most sites have to rely on expensive and sometimes 
ethically-conflicted paid-for services. Moreover the control and 
ownership of any drugs or technologies resulting from the citizen 
science or patient disclosures should be clearly explained to all 
participants, such that the websites do not unknowingly or secretly 
profit off of their member’s efforts. 
CONCLUSION
This paper presents two different but very much related 
emerging technologies: (1) mobile medical device applications that 
take advantage of the growing complexity of every day devices, and 
(2) patient oriented social media that builds off of the exponential 
growth of Web 2.0. 
Both of these technologies (as employed particularly to the 
portion of the population with chronic diseases) can be extremely 
valuable, not only in providing information, support and care to those 
who need it, but also in efficiently creating data for the patients and 
241. ABOUT BADGES, http://www.amazon.com/gp/help/customer/display.html/ref=cm_
dly_lnk?ie=UTF8&nodeId=14279681&pop-up=1 (last visited Nov. 1, 2015). 
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their peers. Both technologies further serve to democratize what has 
traditionally been a paternalistic area of medical care. And, both 
technologies can be particularly helpful for the underserved and 
underrepresented in society. 
Both also present significant challenges in that they can be easily 
abused, but not easily policed and regulated. To this end, this paper 
takes two very different approaches, suggesting that MMAs be less 
heavily regulated than they currently are, to promote innovation, and 
that POSOMS be more heavily regulated to protect their patient 
populations.
Many of the concerns raised with regard to MMAs can be better 
resolved with technological solutions that limit error and protect 
privacy. Whereas many of the concerns raised with regard to 
POSOMS require human intervention and oversight and cannot easily 
be addressed through implementing technological fixes. 
